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A lot of progress has been made in the development and utilization of antimalarial and 
antibacterial drugs. However, reports of increasing resistance to these antimicrobial agents 
are threatening to reduce their overall efficacy. In view of this, the need for new 
antimicrobials is of the paramount importance. Since pantothenate promotes the growth of 
microbes, analogues of this compound that may act as antimetabolites have been synthesized 
and tested for their inhibitory properties against microbial growth. 
 
N-substituted pantothenamides is a class of pantothenate analogues previously synthesized in 
our group that have shown good antibacterial activities, as well as promising inhibition of the 
proliferation of malaria parasites. In this study the chemical and structural diversity of these 
analogues were expanded by preparing N-substituted pantothenamides in which a methyl 
functionality was introduced on either the α- or β-carbon of the β-alanine moiety of 
pantothenate. These compounds were synthesized and purified in parallel, resulting in the 
production of 40 N-substituted α- and β-methylpantothenamides which were investigated as 
potential antibacterial and antimalarial agents. 
 
The growth inhibitory activities of these compounds were first investigated on S. aureus, 
since in the previous study it was shown that N-substituted pantothenamides demonstrated 
remarkable inhibitory activities against this microbe. Next, the impact of these compounds on 
the proliferation of malaria parasites was also investigated to determine if the introduction of 
the methyl group could improve on the poor inhibition exhibited by the first series of 
pantothenamides tested against this organism. 
 
Finally pantoyltauramides, sulfonamide analogues of the pantothenamides, were also 
synthesized and tested for their inhibitory activities against proliferation of malaria parasites 
P. falciparum in vitro. The results show that additional functionalization of pantothenic acid 
may prove to be a viable strategy for improving the inhibitory activity of these 
antimetabolites.  
  





Alhoewel goeie vordering gemaak is in die ontwikkeling en gebruik van middels teen malaria 
en bakteriële infeksies, dreig toenemende weerstand teen sulke verbindings om hul algehele 
doeltreffendheid te verminder. In die lig hiervan, is die behoefte vir 'n nuwe antimikrobiese 
middels is van die allergrootste belang. Aangesien pantoteensuur die groei van mikrobes 
bevorder, is strukturele analoë van hierdie verbinding wat kan optree as antimetaboliete 
gesintetiseer en getoets vir hul inhiberende eienskappe teen mikrobiese groei. 
 
N-Gesubstitueerde pantoteenamiede is 'n klas van pantoteensuur-analoë wat voorheen in ons 
groep gesintetiseer is en goeie antibakteriese aktiwiteite, sowel as belowende inhibisie van 
die vermeerdering van malaria-parasiete, getoon het. In hierdie studie is die chemiese en 
strukturele diversiteit van hierdie analoë uitgebrei deur die bereiding van N-gesubstitueerde 
pantoteenamiede waarby 'n metielgroep funksie op die α- of β-koolstof van die β-alanien 
gedeelte van pantoteensuur aangebring is. Hierdie verbindings is in parallel gesintetiseer en 
gesuiwer om sodoende 40 gesubstitueerde α- en β-metielpantoteenamiede te produseer wat 
gevolglik as moontlike antibakteriese en anti-malaria agente ondersoek is. 
 
Die groei-inhiberende aktiwiteite van hierdie verbindings is eers op S. aureus ondersoek, 
aangesien 'n vorige studie het getoon dat die N-gesubstitueerde pantoteenamiede 
merkwaardige inhiberende aktiwiteite teen hierdie bakterie toon. Daarna was die impak van 
hierdie verbindings ook op die vermeerdering van malaria-parasiete ondersoek om te bepaal 
of die installering van die metielgroep die swak inhibisie wat die eerste reeks van 
pantoteenamiede teen hierdie organisme getoon het, kon verbeter. 
 
Ten slotte is pantoïeltauramiede, sulfoonamied-analoë van die pantoteenamiede, ook 
gesintetiseer en getoets vir hul effek op die in vitro vermeerdering van P. falciparum malaria-
parasiete. Die resultate toon dat die funksionalisering van pantoteensuur 'n lewensvatbare 










This research project would not have been possible without the guidance and the help of 
several individuals who in one way or another contributed and extended their valuable 
assistance in the preparation and completion of this study. 
 
First and foremost, my sincere gratitude and appreciation to Prof. Erick Strauss whose 
sincerity and encouragement I will never forget. Prof. E Strauss has been offering invaluable 
assistance, support and guidance throughout my study. 
 
I would also like to extend my deepest gratitude to the members of the Strauss lab, without 
their assistance this study would not have been a success. 
 
My sincere gratitude goes to Cristiano Macuamule for all the help with P. falciparum 
experiments. 
 
I am truly indebted and thankful to University of Malawi College of Medicine, NRF, and 
Prof. Erick Strauss for financial assistance. 
 
I would like to thank my parents and family members for their prayers and encouragement 













Stellenbosch University  http://scholar.sun.ac.za
vi 
 
Table of contents  
Chapter 1: A General Introduction 
1.1  Asexual (intraerythrocytic) cycle of P. falciparum ........................................................ 2 
1.2 Pantothenate utilization as a target for antimalarial drug development .......................... 4 
Objective and outline ................................................................................................................. 6 
Chapter 2: Literature Review 
2.1 Coenzyme A as a metabolic cofactor .............................................................................. 7 
2.2 Pantothenate as CoA pre-cursor ...................................................................................... 8 
2.3 CoA biosynthesis in bacteria .......................................................................................... 9 
2.4 Pantetheine as CoA precursor ....................................................................................... 10 
2.5 CoA biosynthesis in malaria parasites .......................................................................... 12 
2.6 CoA biosynthesis as a target for anti-microbial drug development .............................. 13 
2.6.1 Pantothenate uptake as target ................................................................................ 13 
2.6.2 Pantothenate phosphorylation via pantothenate kinase (PanK) as target .............. 13 
2.6.2.1 Type I Pantothenate Kinase (PanK-I) ................................................................ 14 
2.6.2.2 Type II Pantothenate Kinase (PanK-II) ............................................................. 15 
2.6.2.3 Type III Pantothenate Kinase (PanK-III) ........................................................... 16 
2.6.3 CoA utilization as target ........................................................................................ 17 
2.7 Conclusion .................................................................................................................... 17 
2.8 Pantoyltaurine and related compounds ......................................................................... 18 
2.9 N-Pantoyl-substituted amines ....................................................................................... 21 
2.10 Pantoylhydrazide and related compounds .................................................................... 23 
2.11 Pantothenones and related compounds ......................................................................... 23 
2.12 Analogues of pantothenic acid with a modified pantoyl moieties ................................ 24 
2.13 Analogues of pantothenic acid with a modified β-alanine moiety ............................... 26 
2.14 Pantothenamides as antimicrobial agents ..................................................................... 27 
2.15 Conclusion .................................................................................................................... 31 
Stellenbosch University  http://scholar.sun.ac.za
vii 
 
Chapter 3: Results and Discussion 
3.1 Parallel Synthesis of α- and β-methyl pantothenamides .................................................... 33 
3.1.1 Synthesis of α- and β-methyl S-phenylthiopantothenate ....................................... 33 
3.1.2 Synthesis and purification of alkyl N-substituted pantothenamides ..................... 35 
3.2 Inhibitory effects of N-substituted α- and β-methylpantothen-amides against bacterial 
growth ...................................................................................................................................... 38 
3.2.1 Inhibitory effects of N-substituted α- and β-methylpantotenamides against P. 
falciparum growth ................................................................................................................ 42 
3.3 Parallel synthesis of pantoyltauramides ........................................................................ 49 
3.3.1 Attempt 1: Synthesis of pantoyltauramides from pantoylcysteamine via the 
corresponding sulfonyl chloride ........................................................................................... 50 
3.3.2 Attempt 2: Synthesis of pantoyltauramides from pantoylcysteamine via the 
corresponding sulfonyl chlorides and pentafluorophenol ester ............................................ 51 
3.3.3 Attempt 3: Synthesis of pantoyltauramides by activation of pantoyltaurine ......... 53 
3.3.4 Synthesis of pantoyltauramides by modification of taurine:  original synthetic 
methods.. .............................................................................................................................. 56 
3.3.5 Attempt 4: Synthesis of pantoyltauramides by modification of taurine:  using 
modified protection and activation strategies ....................................................................... 57 
3.3.5.1 Protection and activation of taurine ................................................................... 57 
3.3.5.2 Synthesis of Cbz-tauramides by aminolysis of Cbz-tauryl fluoride .................. 59 
3.3.5.3 Synthesis of tauramides by deprotection of the Cbz-tauramides ....................... 61 
3.3.5.4 Synthesis of pantoyltauramides from tauramides .............................................. 62 
3.3.6 Conclusion ............................................................................................................. 63 
3.4 Inhibitory effects of N-substituted pantoyltauramides against P. falciparum .............. 63 
3.5 Conclusion .................................................................................................................... 65 
Chapter 4: Experimental 
4.1 Synthetic preparation of α- and β-methyl pantothenate thioesters ............................... 66 
4.1.1 S-Phenyl α-methylthiopantothenate (22) ............................................................... 66 
Stellenbosch University  http://scholar.sun.ac.za
viii 
 
4.1.1.1 α-Methylpantothenic acid (21) ........................................................................... 66 
4.1.1.2 S-Phenyl α-methylthiopantothenate (22) ........................................................... 67 
4.1.2 S-Phenyl β-methylthiopantothenate (25) ............................................................... 68 
4.1.2.1 β-Methylpantothenic acid (24) ........................................................................... 68 
4.1.2.2 S-Phenyl β-methylthiopantothenate (25) .......................................................... 68 
4.2 Parallel synthesis and purification of α- and β-methylpantothen-amides ..................... 68 
4.2.1 General procedure .................................................................................................. 68 
4.2.2 Purification method ............................................................................................... 70 
4.3 Synthetic preparation of pantoyltauramides ................................................................. 73 
4.3.1 Synthesis and activation of N-carbobenzoxy taurine ............................................ 73 
4.3.2 Synthesis of N-carbobenzoxy N´-substituted tauramides ...................................... 74 
4.3.3 Synthesis of N-substituted tauramides ................................................................... 77 
4.3.4 Synthesis of N-substituted pantoyltauramides ....................................................... 78 
4.4 P. falciparum cell culture .............................................................................................. 79 
4.5 P. falciparum in vitro growth inhibition assays ............................................................ 79 
4.6 Bacterial growth inhibition assays ................................................................................ 80 
Chapter 5: Conclusions 
5.1  Summary of results ...................................................................................................... 81 
5.2  Future research possibilities ......................................................................................... 81 
References ………………………………………………………………………………….. 80 






Stellenbosch University  http://scholar.sun.ac.za
ix 
 
List of abbreviations 
 
ACPs   Acyl carrier proteins 
ADP   Adenosine 5’-diphosphate 
AMP   Adenosine 5’-monophosphate 
ASKHA                      Acetate and sugar kinase/hsp70/actin superfamily    
ATP   Adenosine 5’-triphosphate 
CoA   Coenzyme A 
CoaA   Pantothenate kinase 
CoaB   Phosphopantothenoylcysteine synthetase (also PPC-S) 
CoaBC             Phosphopantothenoylcysteine synthetase/ 
   Phosphopantothenoylcysteine decarboxylase (also Dfp) 
CoaC   Phosphopantothenoylcysteine decarboxylase (also PPC-DC) 
CoaD   Phosphopantetheine adenylytransferase (also PPAT) 
CoaE   Dephospho-coenzyme A kinase (also DPCK) 
DAST                          Diethylaminosulfur trifluoride 
DMF   N,N-Dimethylformamide 
DMSO                         Dimethyl sulfoxide 
DNA                            Deoxyribonucleic acid 
DPPA   Diphenylphosphorylazide 
ESI-MS  Electronspray Ionization Mass Spectroscopy 
FAS   Fatty acid synthase 
kcat   Turnover number 
Ka   Affinity constant 
KM   Michaelis constant 
LC-MS   Liquid Chromatography Mass Spectroscopy 
MIC                             Minimum inhibitory concentration 
NADH   Nicotinamide adenine dinucleotide (reduced) 
NPP                             New permeability pathway 
NMR   Nuclear Magnetic Resonance Spectroscopy 
OD   Optical density 
PanK   Pantothenate kinase 
RNA                            Ribonucleic acid 
TLC                             Thin layer chromatography 
Stellenbosch University  http://scholar.sun.ac.za
1 
 
C h a p t e r  1 
A General Introduction 
 
It has been estimated that about one million deaths are attributed to malaria per year, with 
Africa and Asia registering high rates of mortality and morbidity (1, 2). Malaria is caused by 
a protozoon of the genus Plasmodium, of which five species have been identified to cause 
infections in humans (1, 2). Of these, P. falciparum causes more deaths followed by P. vivax 
(1, 2). Infection with malaria occurs when parasites carried by a female anopheles mosquito 
are transmitted to humans by injection into the blood stream during a blood meal (1, 3, 4).  
 
 
Figure 1.1. Life cycle of the malaria parasite P. falciparum, and its pathogenesis. Figure 
reproduced from Ref. 3. 
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While in the blood stream, the parasites in the form of sporozoites invade liver cells and take 
some time to develop and multiply to generate  thousands of merozoites (Fig. 1.1) (3, 4). This 
creates pressure in the liver cells which as a result swell and burst, thereby forcing the 
merozoites out and into circulation. While in the blood stream, the merozoites then attack the 
erythrocytes of the host, and in the process the asexual replication cycle (intraerythrocytic 
stage) begins (Fig. 1.2) (1, 3-5). This stage of the parasite life cycle is characterized by onset 
of clinical symptoms including fevers and anemia, amongst others (1, 3). 




Figure 1.2. Different stages of the asexual cycle of P. falciparum (5). The cycle is initiated by 
merozoites after invading the erythrocyte (a). The parasite settles into the erythrocyte cytosol in such 
a way that it appears as a ring and this is therefore called the ring stage (b). The ring stage parasite 
develops into a trophozoite, which causes the erythrocytes lose its usual biconcave shape (c). The 
trophozoite then develops into a schizont (d), which is characterized by multiplication of the parasite 
into merozoites, which forces the host erythrocyte to swell and burst, releasing the merozoites back 
into circulation (e). Figure reproduced from Ref. 5. 
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Various studies aimed at developing a vaccine for malaria have been carried out, and many 
more are ongoing. However, malaria vaccine development still remains at an early stage due 
to several factors that have hindered its progress (1, 2). This includes the complex life cycle 
of the parasite as well as the difficulty in selecting a suitable target for vaccine development 
(2). Currently, the only means of controlling malaria is by means of anti-malarial drugs to 
check and treat the disease (1, 2), and through the use of insecticides and mosquito nets to 
prevent contact between mosquitoes and humans (6). 
 
Although a lot of progress has been registered in the development and use of anti-malarial 
drugs, increasing resistance is threatening to reduce their overall efficacy (1, 2, 6). 
Previously, chloroquine was regarded as the best anti-malarial drug available on the market; 
however, the emergence of chloroquine drug resistance has rendered the drug to be non-
effective (7). In fact, it has been reported that P. falciparum has developed resistance to 
almost all the classes of anti-malarial drugs with the exception of artemisinin (6), and because 
of this, anti-malarial chemotherapy is increasingly relying on it as a “treatment of last resort” 
(7). However, in recent studies cases of reduced sensitivity to artemisinins were also reported. 
This implies that the utility of the artemisinins may soon also be reduced as far as treating 
malaria is concerned (8, 9). 
 
With this background, there is a need to develop new anti-malarial drugs that could be co-
administered with artemisinin, so as to increase its life span as an effective drug (9). Since 
there is high possibility that new drugs developed against existing targets will be disposed to 
the already available resistance as well, emphasis is being directed at developing drugs that 
would act against novel targets (1). 
 
Various studies have targeted the asexual erythrocytic stage of P. falciparum (Fig. 1.2) for 
anti-malarial drug development. This is because during this stage of the life cycle, parasites 
can be maintained in continuous culture in vitro (5, 10). In addition, studies have also shown 
that the parasite replicates during this stage of the cycle, and therefore requires a vibrant 
metabolism. During this phase of the life cycle, the parasite has to synthesize DNA, RNA, 
proteins and lipids (1, 5) through a variety of metabolic processes, many of which have been 
targeted as novel targets for anti-malarial drug development. However, for metabolism to 
take place in the parasites, uptake of certain essential nutrients is a pre-requisite. One such 
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important nutrient is pantothenate (vitamin B5) (Fig. 1.3), (1, 6) the precursor of the essential 
cofactor coenzyme A in all organisms, including P. falciparum. 
 
 
Figure 1.3. Structure of pantothenate. 
  
1.2 Pantothenate utilization as a target for antimalarial drug 
development 
Studies have highlighted the importance of pantothenate through in vivo and in vitro studies 
with avian malaria parasites. In this study, it was found that pantothenate was required for 
their survival (11). Other in vitro studies showed that supplementation with calcium 
pantothenate promoted the growth of erythrocytic stage P. lophurae within chick and duck 
erythrocytes (11). Further studies implicated pantothenate for worsening P. gallinaceum 
infection in chickens fed on a diet supplemented with pantothenate, implying that 
pantothenate promoted survival of the parasites, and hence the severity of the infection (12).  
Furthermore, it was also shown that extracellular supply of pantothenate in vitro was 
responsible for multiplication of erythrocytic stage of P. falciparum within human 
erythrocytes. In this study, growth of parasites was monitored through the incorporation of 
[
3
H] hypoxanthine (Fig. 1.4) over a 96 hour period (13). 
 




Figure 1.4. [3H]Hypoxanthine incorporation by P. falciparum growing intra-erythrocytically over 96 
hour in culture medium lacking one or more vitamins (13). 
 
As illustrated in Fig. 1.4 above, growth of parasites was inhibited by 82% when all vitamins 
were omitted.  On the other hand, growth of parasites was normal when each of the water-
soluble vitamins were excluded one by one from the extracellular solution, except in the case 
of pantothenate. When this vitamin was excluded from the extracellular solution, growth of 
parasites was inhibited by 80% (13), signifying the importance of pantothenate for growth 
and survival of the parasites. Importantly, because of this discovery, recent studies have 
targeted pantothenate utilization for anti-malarial drug development.  
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Objective and outline 
The main objective of this study was the synthetic preparation and biological evaluation of 
pantothenate analogues – specifically pantothenamides and pantoyltauramides – as potential 
growth inhibitors of malaria parasites and selected bacteria. This work is based on the 
ongoing studies in our group that focuses on the potential of CoA biosynthesis and utilization 
for antimicrobial drug development. 
 
The thesis consists of five chapters: 
 
 Chapter 1 provides a general introduction to the study, its objective and its outline. 
 
 Chapter 2 is a review of the relevant literature, and is presented in two parts. The first 
part is an overview of CoA metabolism and its importance in living systems. It also 
describes and compares the biosynthesis of CoA from pantothenate as a precursor in 
various organisms. In the second part a summary of the pantothenate analogues that 
have been synthesized to date will be provided, with a specific emphasis on the 
analogues that were prepared in the search for anti-malarial drugs. The most recent 
results of the studies from our group on the preparation of pantothenamide-based 
antimalarials are also described. This chapter concludes with a description of the 
specific aims that we set out to accomplish in this study. 
 
 Chapter 3 reports on the results of the synthetic work and on the findings on the 
biological evaluation studies. A discussion of these results is also provided. 
 
 Chapter 4 is a description of all the materials and experimental methods used in this 
study. 
 
 Finally, chapter 5 provides a conclusion. The main findings of this study will be 
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C h a p t e r  2 
LITERATURE REVIEW - PART 1: 
COENZYME A METABOLSIM AND ITS IMPORTANCE IN 
LIVING SYSTEMS 
2.1 Coenzyme A as a metabolic cofactor 
Enzymes are important proteins involved in the catalysis of a variety of metabolic reactions. 
In some reactions, however, participation of a cofactor is a prerequisite. These cofactors may 
be organic molecules, or metal ions in other cases. CoA (Fig. 2.1) is one such cofactor the 
main function of which is to act as a transporter of acyl groups (14). In addition, CoA is also 
important in the activation of acyl groups in numerous biological transformations. Finally, 
CoA has been shown to be the source of 4-phosphopantetheine, a prosthetic group utilized by 
carrier proteins of fatty acid, polyketide and non-ribosomal peptide synthases. Although CoA 




Figure 2.1. Structure of Coenzyme A 
 
The enzymatic reactions of CoA are dependent on the thiol group (sulfhydryl group), which 
is the functional group of the molecule, whereas its adenine portion functions as a recognition 
site for enzymes that bind to CoA (14). CoA esters are actively involved in important 
processes such as fatty acid biosynthesis and degradation, and transcription among others, 
where it serves as substrate for these reactions (14). In addition, long chain CoA esters are 
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involved in the regulation of various cellular functions. One of the acyl derivatives of CoA, 
also known as acetyl-CoA, has been implicated in the resistance to antibiotics such as 
chloramphenicol through acylation. CoA and its acyl derivatives play a pivotal role in 
metabolic reactions (14). 
2.2 Pantothenate as CoA pre-cursor 
Pantothenate (1) (Fig. 1.3), or vitamin B5 as it is sometimes called, is an important small  
molecule involved in nutrition (15), and has been shown to form the core of the structure of 
CoA. Industrially, it is used as a food supplement, whereas the esters and derivatives of its 
reduced form (pantothenol) are used as additives in hair care products (15). Large scale 
production of pantothenate and its derivatives occur via chemical synthesis. In the 1990s, the 
global market production of pantothenate was in excess of 7×10
6
 kg per annum, with most of 
the produced pantothenate being in the form of calcium pantothenate (about 6×10
6
 kg). 
Pantothenol and its derivatives made up the rest (15).  
 
The word “pantothenate” comes from the Greek “pantothen”, meaning “from everywhere” 
due to the fact that most bacteria, including Escherichia coli, Salmonella typhimurium, and 
Corynebacterium glutamicum, species are capable of synthesizing pantothenate de novo. 
Similarly, plants and fungi, including Neurospora crassa and Aspergillus nidulans also 
synthesize pantothenate de novo. However, some microbes are unable to synthesize 
pantothenate, including Streptococcus pneumoniae and Lactobacillus lactis among others. 
Likewise, studies have shown that most animals are also not capable of synthesizing 
pantothenate and as a result rely upon an exogenous source for pantothenate requirements. 
However, due to its ubiquitous nature, no cases of vitamin B5 deficiency have been reported 
(16). In other studies, it was demonstrated that survival of E. coli is not entirely dependent on 
pantothenate biosynthesis because of the fact that the microbe is capable of also using 
exogenous supplies of the vitamin (17). Almost all bacteria contain pantothenate transport 
systems, however, this system is vital for those bacteria that mainly lack the machinery to 
biosynthesize pantothenate de novo, as is the case with Streptococcus pneumonia and 
Haemophilus influenza (6, 17). In E. coli, the pantothenate uptake system is mediated by a 
high affinity (KM ~0.4 µM) Na
+
-stimulated pantothenate transporter which is able to transport 
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2.3 CoA biosynthesis in bacteria 
CoA is biosynthesized in five enzyme-catalyzed steps from pantothenate (Scheme 2.1) (16). 
The first and key step in the pathway involves formation of 4’-phosphopantothenate, a 
reaction catalyzed by pantothenate kinase (PanK). Next, L-cysteine condenses with 4’-
phosphopantothenate producing 4’-phosphopantothenoylcysteine which is subsequently 
decarboxylated to form 4’-phosphopantetheine (16). Two enzymes, 4’-
phosphopantothenoylcysteine synthase (PPCS) and 4’-phosphopantothenoylcysteine 
decarboxylase (PPCDC) catalyse the second and third reactions respectively. The next step 
involves addition of the AMP moiety of ATP to 4’-phosphopantheine to form dephospho-
CoA, a step catalysed by phosphopantetheine adenylyl transferase (PPAT). This is followed 
by phosphorylation by dephospho-CoA kinase (DPCK) at the 3’-OH of the ribose moiety 
resulting in the production of CoA (16). 
 






Scheme 2.1. Pathway for biosynthesis of CoA from pantothenate (vitamin B5) 
 
2.4 Pantetheine as CoA precursor 
In bacteria, pantetheine, or its oxidized form, pantethine, is also utilized to produce CoA in 
the so-called CoA salvage pathway (Scheme 2.2). In this pathway, pantetheine is 
phosphorylated by PanK to produce 4’-phosphopantetheine, followed by adenylylation and 
phosphorylation by PPAT and DPCK to form CoA (6). The discovery of this pathway was 
based on studies that showed that pantetheine has growth-promoting activities in lactic acid 
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bacteria grown in the absence of pantothenic acid (18, 19). It has also been reported that E. 
coli has the ability to synthesize CoA by using dietary pantetheine (6, 20). Recently, E. coli 
PanK has been shown to catalyze the phosphorylation of pantetheine to 4’-
phosphopantetheine, with subsequent conversion to dephospho-CoA and CoA using PPAT 
and DPCK respectively (21).  
 
 
Scheme 2.2. CoA salvage pathway using pantetheine as a precursor  
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2.5 CoA biosynthesis in malaria parasites 
As discussed in chapter 1, pantothenate is an essential nutrient of the intra-erythrocytic stage 
of the human malaria parasite Plasmodium falciparum. However, it has been shown that 
pantothenate is not capable of traversing through the membranes of normal uninfected human 
erythrocytes, but is permeable to P. falciparum-infected erythrocytes. This is due to the 
presence of the “new permeability pathways” (NPP), which are induced by the parasite upon 
infection of the host cell (22, 23). Other studies have also shown that the NPP possesses 
broad specificity in that it is permeable to neutral and anionic substances, and consequently 
makes the cell membrane more permeable to a variety of nutrients and metabolic waste 
products. However, NPP do not occur in normal and uninfected erythrocytes (24, 25).  
 
When pantothenate reaches the inside of the host erythrocyte, it is thought to traverse into the 
parasitophorous vacuole through the membrane that surrounds it. At this stage, it is taken up 
by the parasite with the aid of a transporter. This is supported by studies done by Saliba and 
Kirk who demonstrated that uptake of pantothenate by the intracellular parasite occurs via an 
H
+
-coupled transporter. They showed that this transport system possesses a low affinity for 
pantothenate (Km ~23 mM), and that the transport of pantothenate occurs in a 1:1 
stoichiometry with H
+
 (23). Once in the parasite cytosol, pantothenate is phosphorylated by 
PanK (PfPanK) (26) with subsequent conversion to dephospho-CoA (scheme 2.3). It is 
presumed that dephospho-CoA then finally enters the apicoplast where it gets converted to 
CoA. (6). 
 
Scheme 2.3. Pantothenate uptake and utilization by P. falciparum-infected human erythrocyte. 
Figure reproduced from Ref. 5 
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2.6 CoA biosynthesis as a target for anti-microbial drug development 
Due to its essential role in metabolism, and the fact that all organisms have to produce their 
own CoA de novo, CoA biosynthesis has been considered an important potential target for 
drug development.  Three processes have been identified as specific targets: 
 
1. Pantothenate uptake 
2. Pantothenate phosphorylation 
3. CoA utilization 
 
2.6.1 Pantothenate uptake as target 
As discussed before (22), normal human erythrocytes are impermeable to pantothenate. 
However, recent studies have shown that pantothenate can traverse through the membranes of 
normal human erythrocytes, although the uptake process is still very slow as compared to the 
speedy uptake of pantothenate by P. falciparum-infected erythrocytes via the “NPP” (27). In 
addition, comparison of the mammalian pantothenate transport system to that of P. 
falciparum showed that mammalian cells take up pantothenate via a Na
+
: pantothenate 
symport system, compared to the H
+
:pantothenate system in P. falciparum. Furthermore, it 
was also shown that the mammalian pantothenate transport systems have high affinity for 
substrates with a KM of 2-5 µM (28-30) in contrast with pantothenate transport system in P. 
falciparum which exhibits low affinity for its substrate (KM ~ 23 mM) (23). Since the 
pantothenate requirement of the infected erythrocyte is different from health erythrocytes, 
these remarkable differences can be exploited as a target for drug design. 
  
2.6.2 Pantothenate phosphorylation via pantothenate kinase (PanK) as 
target 
As previously stated, pantothenate kinase (PanK) is an enzyme that catalyses the 
phosphorylation of pantothenate to form 4-phosphopantothenate in the CoA biosynthetic 
pathway. The process is ATP-dependent, and is the first committed step in the biosynthesis of 
CoA (scheme 2.4) (16). 
 




Scheme 2.4: Conversion of pantothenate to 4-phosphopantothenate by PanK. 
 
Three types of PanK can be distinguished based on the differences in their primary 
sequences, structural motifs and folds, and kinetic properties (31). Importantly, despite the 
fact that the eukaryotic and prokaryotic PanKs are structurally different, they are both 
feedback-inhibited by CoA or its thioesters, thereby acting as regulators of homeostasis and 
CoA biosynthetic processes in the cell (32, 33). Interestingly, some prokaryotes contain genes 
that encode for two different PanK’s, as in the case of Bacillus subtilis, and Mycobacterium 
tuberculosis (31), which contain both type I and III PanKs.  
 
The fact that CoA biosynthesis depends on PanK as a key rate-determining enzyme suggests 
that targeting this enzyme for drug development may be possible. Moreover, since the human 
and P. falciparum PanK (PfPanK) have low sequence similarity, targeting PfPanK for drug 
development seems like an attractive target. However, structurally both the human PanK and 
PfPanK are type II classes of PanKs, indicating that the design of selective inhibitors 
targeting PfPanK may be a challenge. 
 
The biology of PanK types, which has been comprehensively reviewed by Strauss et al (34), 
is discussed in the following subsections. 
 
2.6.2.1 Type I Pantothenate Kinase (PanK-I)    
Type I pantothenate kinases (PanK-I) are commonly found in eubacteria species. The best 
characterized member of this group is the Escherichia coli enzyme (31). PanK-I is encoded 
by coaA gene (33). Structurally, bacterial PanK-I has been shown to be a member of the P-
loop kinase superfamily (32). E. coli PanK-I is a 36 kDa dimer containing identical subunits 
(33), with an A-type ATP binding consensus sequence GXXXXGKS (35). Studies have 
shown that PanK-I is inhibited by CoA, and to a lesser degree by its thioesters in vitro (36). 
In addition, non-esterified CoA is thought to be most effective inhibitor of E. coli PanK, 
whereas acetyl-CoA (37), and malonyl-CoA are the most potent regulators in eukaryotic 
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systems. Moreover, it has been reported that PanK-I enzymes are capable of phosphorylating 
pantothenate analogues known as N-alkylpantothenamides (32). For example; the 
phosphorylation of N-pentyl pantothenamide (N5-Pan) (scheme 2.5) demonstrates the 
reactivity of PanK-I towards pantothenamides (34). 
 
 
Scheme 2.5.  Phosphorylation of N-pentyl pantothenamide by PanK-I 
 
Kinetic analysis studies have revealed that CoA exerts feedback inhibition through 
competitive inhibition of the ATP binding site (38). The ATP binding site has been shown to 
contain lysine 101 as a key residue implicated in the nucleotide substrate and inhibition 
binding (39). Studies on carbon source shift experiments in E. coli demonstrated that CoA is 
the most effective inhibitor of PanK activity in vivo (40). 
 
2.6.2.2 Type II Pantothenate Kinase (PanK-II) 
These enzymes are mainly found in eukaryotes including plants (Arabidopsis thaliana) and 
fungi (Aspergillus nidulans), among others (31). In addition, it has been reported that the 
mammalian PanK belongs to this group, and the best characterized member of the group is 
the murine PanK. Recently, a prokaryotic type II enzyme was identified in Staphylococcus 
aureus (S. aureus) (41). Contrary to PanK-I enzymes which belong to P-loop family of 
kinases, bioinformatics studies predicted that PanK-II is a member of ribonuclease H-like 
family of kinases (42). The R-nase H-like group is slightly related to the ASKHA (acetate 
and sugar kinase/hsp70/actin superfamily) (31). Studies of the crystal structures of the S. 
aureus PanK-AMPPNP complex confirmed these predictions (42). PanK-I and PanK-II share 
little sequence similarity, although both are regulated through feedback inhibition by CoA 
and its thioesters (41), with acetyl-CoA demonstrating high potency. Like PanK-I enzymes, 
PanK-II also recognize pantothenamides as alternative substrates, phosphorylating them to 
allow the formation of inactive CoA analogues (33). 
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2.6.2.3 Type III Pantothenate Kinase (PanK-III) 
The most recent discovery has been the identification of PanK-III in bacteria. This enzyme is 
encoded by the coaX gene, a terminology used to distinguish this enzyme from the PanK-I 
gene (coaA) (32). This enzyme is most commonly found in pathogens such as Helicobacter 
pylori and Pseudomonas aeruginosa (33), and also in Bacillus subtilis (42). PanK-III differs 
from PanK-I and PanK-II in that it is not inhibited by CoA or its thioesters, a property that is 
unique among organisms which contain this type of enzyme (31, 32). Although the KM-
values of PanK-I and PanK-II for their substrates are similar (in the micromolar range), 
PanK-III enzymes show a remarkable high KM for ATP (up to ~10 mM) (33), which in some 
cases constitutes an increase of 30- to 100-fold over PanK-I and PanK-II (31). PanK-III 
enzymes are not inhibited by N5-Pan, nor do they act on it as an alternative substrate (42). 
 
Apart from having an extraordinarily high KM for ATP, CH2Cl2Pank-III enzymes also have a 




) for activity (32). Structural studies 
have shown that PanK-III belongs to the ASKHA superfamily, as confirmed by crystal 
structures of Thermotoga maritima PanK at 2.0-Å resolution (31). Additionally, crystal 
structures of the PanK-III from P. aeruginosa (PaPanK) in complex with pantothenate 
(PaPanK-Pan) also confirmed this (42). The main characteristics of PanK enzymes are 
summarized in table 2.1 (34). 
 
Table 2.1. Comparison of the main characteristics of the three PanK enzymes. 
Attribute 
Type I PanK Type II PanK Type III PanK 
(E. coli PanK) 
(A. nidulans 
PanK ) 
( S. aureus PanK 
- atypical) 
(H. pylori PanK) 
KM (pantothenate 36 ± 4 µM 60 µM 23 µM 5.5 µM 
KM (ATP) 136 ± 15 µM 145 µM 34 µM 7.9 mM 




 1.65 ± 0.09 s
-1






















CoA (less by 
CoA thioesters) 
Acetyl-CoA None None 
Pantothenamides Are substrates Are substrates Are substrates No effect 
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2.6.3 CoA utilization as target 
Fatty acids play a crucial role in cells as precursors for metabolic processes. They are 
synthesized by elongation of acyl chains using malonyl-CoA as a precursor, and fatty acid 
synthase (FAS) catalyzes the elongation process. Previously, it was thought that P. 
falciparum was unable to synthesize fatty acids de novo, instead it survived by scavenging 
fatty acids from the host erythrocyte. However, the discovery of the apicoplast in P. 
falciparum overturned this assumption (43). Molecular and cellular biological analyses aimed 
at understanding the cells of the parasite, as well as the completion of the genome sequences 
of P. falciparum produced results that showed that Plasmodium parasites have the ability to 
synthesize fatty acids de novo. In addition, it was also shown that the parasites contain the 
genes encoding type II FAS, which catalyzes the synthesis of these lipids (44). Furthermore, 
bioinformatics studies showed that the Plasmodium genome contain genes encoding proteins 
with primary sequences showing homology to the orthologs in bacteria and plants that are 
involved in the de novo synthesis of fatty acids. In plants and bacteria, these enzymes form a 
complex that functions as an FAS, known as the type II FAS (44). Studies by Waller and co-
workers (43) showed that P. falciparum relies on type II FAS for de novo fatty acid synthesis. 
On the other hand, FAS in animals including humans appears as a single large polypeptide 
multifunctional protein belonging to type I FAS (43, 44). Interestingly, the fact that type II 
FAS is not available in humans, suggests that the corresponding pathway can be investigated 
as a possible target for antimalarial drug design.  
2.7 Conclusion 
All the three targets in CoA metabolism that have been identified for potential drug 
development, namely pantothenate uptake, pantothenate phosphorylation by PanK and CoA 
utilization may potentially be exploited by the use of compounds that mimic the structure of 
pantothenate. Such pantothenate analogues can act as antagonists (antimetabolites) of CoA by 
virtue of their chemical relationship with the metabolite, or mimic its activities, or inhibit 
enzyme reactions involved in its synthesis or utilization. In the next section the pantothenate 
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LITERATURE REVIEW - PART II:  
PANTOTHENIC ACID ANALOGUES AS ANTIMICROBIAL 
AGENTS 
 
Studies focusing on pantothenic acid analogues as inhibitors of microbial growth were 
initiated in early 1940, and since then many analogues of pantothenic acid have been 
synthesized and tested for their inhibitory properties (6). While many were found to lack 
activity, some promoted the growth of microbes (specifically those that rely on dietary supply 
of pantothenic acid) while other analogues were effective inhibitors (6). A summary of these 
analogues, thoroughly reviewed by Spry et al (6) will be discussed below. An important 
aspect of the study of the inhibitory effects of pantothenate analogues related to the extent to 
which any observed inhibition can be reversed by the addition of pantothenate; in cases 
where an analogue binds to its target less effectively than pantothenate, such a reversal will 
be easy to accomplish with even small amounts of additional pantothenate. In the following 
summary the extent to which inhibition was reversed in this manner will also be highlighted 
in each case. 
2.8 Pantoyltaurine and related compounds 
Pantoyltaurine, 6, is an analogue of pantothenic acid, 1, containing a sulphonic acid group 
(Fig. 2.2) instead of the carboxylate of pantothenic acid. The most basic of these analogues 
was named pantoyltaurine by Barnette and Robinson in 1942 (45). 
 
 
Figure 2.2: Structure of pantoyltaurine 
 
This analogue was found to be effective at inhibiting growth of bacteria which rely on dietary 
supply of pantothenic acid, including Lactobacilus arabinosus and Streptococcus lactis, 
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among others. However, 6 did not negatively affect growth of microbes which synthesize 
their own pantothenic acid, such as E. coli and S. Aureus (46, 47). There was an observed 
variation in potency of 6 against different microbes. This is demonstrated by the fact that 
Lactobacillus arabinosis is fully inhibited at pantoyltaurine concentration of 1000-fold the 
concentration of pantothenate in the medium, while Leuconostoc mesenteroides only showed 
growth inhibition at pantoyltaurine concentration of 162000-fold that of pantothenate (6).  
 
Other studies demonstrated that 6 negatively affected growth of bacteria in vivo, through 
administration of large subcutaneous dose of this compound to rats. On further examination, 
the analogue was found to protect rats from infection caused by a virulent strain of 
Streptococcus haemolyticus (48). In addition, simultaneous administration of pantothenate to 
rats resulted in reversing the therapeutic effects of 6, showing that antibacterial properties 
were due to pantothenate dependent processes. Interestingly, despite a fairly high dose of 6 
administered to rats, the analogue was shown to be non-toxic, and the rats responded well by 
increasing their weight normally throughout the treatment (48). 
 
Since compound 6 demonstrated inhibitory characteristics both in vivo and in vitro, and 
considering the fact that the analogue was easily synthesized, this was enough motivation to 
prepare more analogues similar to 6 structurally. As a result, pantoyltauramide 7, (Fig. 2.3), a 
sulphonamide analogue of pantothenic acid was prepared (45, 49). Other compounds which 
resulted from substitutions of sulphonic acid group of pantoyltaurine with a thiol, a 
disulphide, and a sulphone, were also synthesized. The majority of these compounds were 
effective at inhibiting bacterial growth in vivo, of microbes which need supply of exogenous 
pantothenic acid such as Streptococcus haemoliticus, and Lactobacillus arabinosus among 
others; and in vitro, in strains such as Corynebacterium diptheriae. However, the 




Figure 2.3: Structure of pantoyltauramide 
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Since the discovery that pantothenic acid is required for the survival of the intra-erythrocytic 
stage of malaria parasites, studies have been intensively conducted in search of compounds 
with antimalarial activity that would affect the utilization of pantothenic acid by the parasites. 
The quest for these compounds led to the synthesis of pantothenic acid analogues such as 
pantoyltaurine and pantoyltauramide which were then tested against malaria parasites.  
 
When pantoyltaurine was tested against P. relictum-infected canaries, P. lophurae-infected 
ducks and P. gallinaceum-infected chickens for its antiplasmodial activities, the analogue 
demonstrated inactivity. Another analogue, pantoyltauramide, 7, (Fig. 2.3) was shown to 
inhibit the growth of P. gallinaceum after intravenous administration of this analogue. 
However, the antiplasmodial activity of the analogue was reversed in the presence of 
increased concentration of pantothenate (51). 
 
In other studies, N-substituted pantoyltauramides, 8, were prepared (Fig. 2.4), and when 
tested for antiplasmodial activity in P. gallinaceum infected chicks through intravenous 
administration, it was found that compound 8a inhibited growth of the parasites. However, 
the activity of these analogues was less as compared to the activity of pantoyltauramide (51).  
 
In another attempt, Winterbottom et al synthesized other N-substituted pantoyltauramides 
(Fig. 2.4) which were found to be more active against P. gallinaceum-infected chickens than 
pantoyltaurine and pantoyltauramide (51). 
 
 
Figure 2.4: N-substituted pantoyltauramides 
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According to Brackett et al (12), a few of the N-substituted pantoyltauramides (Fig. 2.4) 
demonstrated higher activity compared to the activity of the antimalarial quinine, and it was 
also found that the most active compound, 8d, was four times more active than quinine, and 
sixteen times more active against P. gallinaceum blood-induced infection. In addition, 8d 
suppressed the growth of P. lophurae in vitro, when incorporated into the culture at a 
concentration of 360 µM. Nevertheless, supplementation of 40 µM pantothenate to the 
culture medium reversed the antiplasmodial activity (12). Furthermore, 8d also inhibited the 
proliferation of the monkey malaria parasite P. coatneyi and the human malaria parasite P. 
falciparum within monkey and human erythrocytes respectively. When the cultures were 
incubated with 8d in concentrations of between 220 and 820 µM for two days, there was a 
remarkable reduction in parasitemia levels of these parasites. However, the antiplasmodial 
activity of P. coatneyi was to some extent reversed in the presence of 40-65 µM pantothenate 
in the cultures (12).  
2.9 N-Pantoyl-substituted amines 
N-Pantoyl substituted amines constitute all analogues in which the β-alanine moiety of 
pantothenate has been replaced by another amine. The most important of these is pantothenol, 
9, (the alcohol analogue of pantothenic acid) first prepared by Pfaltz in1943.  
 
 
Figure 2.5: Structure of pantothenol. 
 
This analogue was successful in preventing achromatrichia (loss of pigment in hair) of black 
rats, the activity attributed to the oxidation of 9 to pantothenic acid in the animal. In addition, 
compound 9 demonstrated inhibitory activities towards growth of lactic acid bacteria 
including Leuconostoc mesenteroides, Lactobacillus acidophilus, and Lactobacillus 
arabinosus in vitro. However, in a manner similar to pantoyltaurine, growth inhibition was 
competitive with respect to pantothenic acid (52, 53). Further studies with compound 9 
demonstrated that the analogue was inefficient at inhibiting the growth of the yeast 
Saccharomyces cerevisiae. On the other hand, at 300 times the concentration of pantothenate, 
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the analogue demonstrated more potency as compared to pantoyltaurine when tested against 
Leuconostoc mesenteroides and completely inhibited the growth of this organism (52, 53).  
 
Since compound 9 can be converted back to pantothenic acid in some organisms, and since 
the analogue has been shown to be effective at inhibiting growth of different bacteria in vitro, 
Saliba et al (2005) evaluated the effect of this analogue as an inhibitor of the growth of the 
malaria parasite P. falciparum in vitro (54). In this study, compound 9 was administered 
orally to mice suffering from murine parasite Plasmodium vinckei vinckei infection. Results 
showed that the analogue was effective at inhibiting growth of the parasites in vitro. 
Additionally, the analogue was also able to suppress multiplication of parasites in vivo 
through reduction of parasitemia levels in mice subjected to daily oral administration of 
pantothenol for 4 days after infection (54). 
 
In other studies, other N-pantoyl-substituted amines, 10, (Fig. 2.6) were also prepared as 
pantothenic acid analogues.  
 
 
Figure 2.6: Structure of N-pantoyl substituted amine 
 
These analogues were prepared by reacting pantolactone with a variety of amines including 
hydroxyamines, alkylamines, as well as amino acids (6). Many of these compounds 
demonstrated inhibitory activities against lactic acid bacteria, but growth inhibition occurred 
in a competitive manner with respect to pantothenic acid (6).  
 
In studies conducted by Fissekis et al (6, 55), analogues of pantothenic acid were prepared by 
reacting pantolactone with a variety of arylalkylamines. These N-pantoylaryl alkylamines had 
inhibitory activities against growth of lactic acid bacteria, and again it was found that the 
inhibition was overcome by increasing pantothenate concentration (6, 55). 
 
Further studies in search of pantothenic acid analogues were conducted by Parker et al (56). 
In this study, a variety of functional groups including chloro- and nitro- groups were attached 
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to the phenyl group of N-pantoylarylalkylamines, forming analogues called N-pantoyl 
(substituted-phenyl) alkylamines (56). By using two microorganisms, Lactobacillus 
arabinosus and Leuconostoc mesenteroides, the potency of these analogues was evaluated. 
Further analysis showed that all analogues were effective at inhibiting growth of lactic acid 
bacteria. However, growth inhibition was competitive with respect to pantothenic acid. 
Additionally, it was further demonstrated that analogues with chloro- and nitro-substituents 
were more potent against these two microorganisms (56).  
2.10 Pantoylhydrazide and related compounds 
In an attempt to produce more potent analogues of pantothenic acid, other groups (49) 
generated various analogues, including pantoylhydrazide, 11 (Fig. 2.7).  
 
 
Figure 2.7: Structure of pantoylhydrazide 
 
When compound 11 was tested on microbes, it demonstrated slightly more potent inhibitory 
activities against the growth of Lactobacillus casei in vitro than pantoyltaurine in the 
presence of 10 µM pantothenate.  However, when the extracellular supply of pantothenate 
was reduced to 0.1 µM, the analogue demonstrated 50 times more potency, clearly showing 
that the activity was antagonized by pantothenate (49). Furthermore, 11 negatively affected 
growth of Streptococcus pyogenes in vitro, but failed to reverse bacterial activity in rats 
infected with Streptococcus pyogenes infection after subcutaneous administration in four 
doses of 1 g/kg body mass over a 12 hour period after infection (49). 
2.11 Pantothenones and related compounds 
In other studies, other groups substituted the carboxyl group of pantothenic acid with a 
variety of alkylketones. In this manner, two pantothenic acid ketone analogues were 
prepared; first a methyl ketone analogue called methylpantothenone, 12a,  was synthesized 
(Fig. 2.8) which demonstrated toxic effects towards the growth of the bacterium 
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Lactobacillus casei and the yeast Saccharomyces cerevisiae, with microbial growth lowered 
to 50% at concentrations of 12a between 460 and 2300 µM. Importantly, the activity of the 
analogue was not affected by pantothenic acid (57).  
 
                                
Figure 2.8: Structures of methylpantothenone and phenylpantothenone 
 
Secondly, a phenylketone analogue termed phenylpantothenone, 12b, (Fig. 2.8) was 
synthesized and showed growth inhibition of several bacteria that depends upon availability 
of exogenous pantothenic acid for survival (such as L. casei), as well as a variety of 
microorganisms which are capable of synthesizing their own pantothenic acid, such as E. 
coli. It was shown that at 0.2 µM pantothenic acid concentrations, growth of L. casei, E. coli, 
and S. aureus was lowered to half maximum at phenylpantothenone concenterations of 190, 
7200, and 500 µM respectively. When compared to 12a, the inhibitory properties of 12b were 
reversed by addition of pantothenic acid (57). 
2.12 Analogues of pantothenic acid with a modified pantoyl moieties 
Most pantothenic acid analogues have been produced as a result of structural modifications to 
the β-alanine moiety of pantothenic acid. However, some analogues have been produced as a 
result of structural modification to the pantoyl group of pantothenic acid (6). 
 
One such pantoyl-modified analogue, ω-methylpantothenic acid, 13, proved to be an effective 
antagonist of pantothenic acid, and inhibited growth of lactic acid bacteria in vitro (58).  
 
 
Figure 2.9: Structure of ω-methylpantothenic acid. 
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Furthermore, compound 13 also showed activities that prevented the proliferation of β-
haemolytic Streptococcus in mice when administered in the diet (59). Since 13 was seen to be 
effective at inhibiting bacterial growth in vitro, and growth of β-haemolytic Streptococci in 
vivo, a variety of ω-substituted analogues were prepared by replacing the methyl group of 13 
with alkyl or aryl groups. Although the resulting analogues demonstrated growth inhibition 
against lactic acid bacteria, they were less active as compared to ω-methylpantothenic acid 
(60).  
 
In another effort, Fissekis et al (61) prepared an analogue in which the methyl group of ω-
methylpantothenic acid was replaced with a cyclopentane ring. The resulting compound 
demonstrated inhibitory activities against the growth of bacteria including Streptococcus 
lactis and Lactobacillus arabinosus, however, supplementation of pantothenate reversed the 
inhibitory activities of the compound (61). 
 
When modifications made to the pantoyl-moiety of pantothenic acid were incorporated into 
inhibitory pantothenic acid analogues whose β-alanine moiety was already modified, mixed 
results were obtained. For example; homopantoyltaurine, 14, (Fig. 2.10), containing an extra 
carbon unit introduced into pantoyl group of pantoyltaurine, was shown to inhibit pantothenic 
acid utilization (45, 62).  
 
 
Figure 2.10: Structure of homopantoyltaurine 
 
In addition, the analogue also inhibited growth of Streptococcus haemolyticus, although its 
activity was lower than that of pantoyltaurine. Furthermore, homopantoyltaurine inhibited 
growth of Diplococcus pneumonia and certain strains of Corynebacterium diptheriae, with 
less activity than pantoyltaurine (62). 
 
Recently, Akinusi and co-workers (2011) synthesized a small library of N-substituted 
pantothenamides, 15, by replacing the geminal dimethyl groups on the pantoyl moiety with 
various alkyl substituents (Fig. 2.11) (63). 




Figure 2.11; Modifications to the germinal dimethyl groups on the pantoyl moiety of N-substituted 
pantothenamides. R1,R2, R3 = alkyl substituents 
 
When these analogues were tested for their biological activity, it was found that N5-Pan (R1 
and R2 = Me, R3 = pentylamine) inhibited the growth of S. aureus with a MIC activity of 7 
µM. However, when the pro-R methyl group (R2 substituent) was substituted with an allyl 
group, the resulting analogue was twice as potent as the parent N5-Pan, and inhibited the 
growth of S. aureus with an MIC of 3.2 µM. Substitution of both the geminal dimethyl 
groups with allyl substituent produced a diallyl-substituted derivative with weak activity, 
having an MIC-value of 376 µM. Further attempts to vary R1 with various substituents 
proved futile, as the resulting analogues were all found to be devoid of activity. In this study, 
most of the analogues were produced as a result of single substitution at R2, with most 
derivatives showing increased activity (63). 
2.13 Analogues of pantothenic acid with a modified β-alanine moiety 
An interesting pantothenic acid analogue extracted from the fungus Seimatosporium sp strain 
CL28611 was found to have antibacterial activities against S. aureus. This analogue, called 
CJ-15,801, 16, (Fig. 2.12), differs from the parent pantothenic acid structure simply by 
possessing a double bond between the α- and β-carbons on the β-alanine moiety of 
pantothenic acid (64).  
 
 
Figure 2.12: Structure of CJ-15,801 
 
In a study conducted by Saliba and Kirk (2005), compound 16 was shown to inhibit 
proliferation of P. falciparum at the intraerythrocytic stage of the life cycle. In this study, 
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growth inhibition was monitored through incorporation of [
3
H]hypoxanthine (64). It was 
demonstrated that the analogue inhibited growth of the parasites with an IC50 of 39 ± 3 µM, 
however, this occurred in the presence of 1 µM of pantothenic acid (64). Furthermore, it was 
also shown that the proliferation of the parasites was completely inhibited when the 
concentration of the analogue was increased to more than ~250 µM. When the same 
concentration of the analogue was used on a mammalian (rat hepatoma; HTC) cell line, no 
inhibitory activities were observed (64). It was also demonstrated that the antiplasmodial 
effect of CJ-15,801 was reversed in the presence of increased concentrations of pantothenic 
acid in the medium, for example, 100 to 500 µM. This suggests that the antiplasmodial 
effects of CJ-15,801 are exerted by blocking utilization of pantothenic acid by the parasites 
(64).  
2.14 Pantothenamides as antimicrobial agents 
Pantothenamides are important pantothenic acid analogues in which the carboxylate has been 
replaced by N-substituted amides, as in the case of N-pentylpantothenamide (N5-Pan) and N-
heptylpantothenamide (N7-Pan) for example (65). These analogues generally referred to as 
N-substituted pantothenamides have been utilized in many studies as inhibitors of bacterial 
growth. It has been shown that these analogues have an effect down-stream of CoA 
biosynthesis, as they are converted by the CoA biosynthetic enzymes into corresponding CoA 
analogues which act as inhibitors of CoA-dependent enzymes. (66). specifically, these 
analogues all lack a sulfhydryl (-SH) group that can act as a functional group. This renders 
them inactive, since they cannot transfer acyl groups from one reaction to the next. 
Consequently, fatty acid metabolism is inhibited, since inactive prosthetic groups are 
transferred to the acyl carrier proteins (ACPs) which play a pivotal role in these processes 
(66).   
 
In studies conducted by Clifton et al in 1970 (67), a variety of N-substituted pantothenamides 
were prepared. When these analogues were tested for activity, it was shown that they 
negatively affected the growth of lactic acid bacteria including Lactobacillus arabinosus and 
Lactobacillus casei. However, its activity was reversed by pantothenic acid in a competitive 
manner (67). Of the synthesized compounds, N-nonylpantothenamide and N-
phenylpantothenamide were shown to be highly active and caused complete inhibition of 
growth of Lactobacillus casei at a concentration of ~20 µM (67). In addition, other 
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pantothenamides were shown to inhibit the growth of E. coli, including N-
pentylpantothenamide and N-heptylpantothenamide. It was also shown that these analogues 
exhibited exceptional properties in that at lower concentration of the analogues, their 
inhibition activities were reversed by pantothenic acid, whereas the analogues were 
irreversibly toxic at higher concentrations. N-pentylpantothenamide exhibited the highest 
potency against E. coli, inhibiting growth completely at 2 µM (67). 
 
A variety of pantothenic acid analogues structurally similar to pantothenamides were 
prepared by Sergent et al (1975) by substituting the terminal amide functionality with an N-
substituted carbamate or ureido group. The resulting analogues demonstrated inhibitory 
activities against lactic acid bacteria including Lactobacillus plantarum and Pediococcus 
cerevisiae, but did not inhibit E. coli (6). However, the inhibitory activity of the analogues 
was antagonized by pantothenic acid in a competitive manner. On assessing the efficiency of 
these analogues as inhibitors, it was shown that the carbamate analogues were more 
successful as inhibitors than the ureido analogues, completely inhibiting growth of 
Lactobacillus plantarum at a concentration of 2 µM (6). 
 
Studies conducted by Strauss and Begley (2002) showed that the analogue N-
pentylpantothenamide (N5-Pan) did not act as an inhibitor of the CoA biosynthetic enzymes 
PanK, PPAT, and DPCK in the CoA biosynthetic pathway, but rather acted as a substrate of 
these enzymes which resulted in its conversion to the CoA analogue ethyldethia-CoA, 17,   
(Fig. 2.13) (68). 
 
  
Figure 2.13. Structure of the inactive CoA analogue, ethyldethia-CoA (6). 




In the same study, they demonstrated that the conversion of N5-Pan to 17 occurred 10.5-fold 
faster than biosynthesis of CoA from pantothenic acid, implying that biosynthesis of 
ethyldethia-CoA could be competitive with respect to conversion of pantothenate to CoA in 
the cell (68). With this result, Strauss and Begley therefore suggested that the toxic effects of 
N5-Pan were as a result of the analogue’s conversion to compound 17, which exerts its 
influence by inhibiting CoA and acetyl-CoA utilizing enzymes (68). N5-Pan and N7-Pan 
efficiently inhibited growth of bacteria, and are believed to act through conversion of these 
analogues by PanK to intermediates which later are implicated in the production of CoA 
analogues which are not active (35).  
 
In other studies, Ivey et al (2004) demonstrated that N5-Pan and N7-Pan were successful 
competitive inhibitors of E. coli PanK with an IC50 of 60 µM, and the inhibitors were shown 
to be competitive with respect to pantothenate (35). Determination of an experimental KM for 
N5-Pan and N7-Pan as substrates for PanK revealed that these analogues were alternative 
substrates, showing KM values of 140 and 124 µM respectively, as compared to the KM for 
pantothenate which was 41 µM (35).  
 
In other studies, N5-Pan and N7-Pan demonstrated inhibitory activities against S. aureus 
PanK with an IC50 in the low micromolar range (69). Similarly, Leonardi et al (2005) 
demonstrated the inhibitory activities of N5-Pan and N7-Pan on S. aureus PanK with IC50 
values of 3.5 and 4.8 µM respectively. In addition, these analogues were found to be both 
inhibitors and substrates for S. aureus PanK (70). By using broth microdilution assays, MIC 
values of 0.16 and 25 µM of N5-Pan and N7-Pan were determined against S. aureus strain 
RN4220. Supplementation of the growth medium with 50 µM pantothenate resulted in a 
reduced efficacy of these analogues, showing that the primary target of these analogues is 
pantothenate metabolism (70). Subsequently, it has been demonstrated that the toxic effects 
of N7-Pan in S. aureus is a result of fatty acid synthesis inhibition (70). 
 
Studies performed by Brand and Strauss (71) and Hong et al (33), which involved 
characterization of the type-III PanK enzymes expressed by Bacillus subtilis, Helicobacter 
pylori, and Pseudomonas aeruginosa, found that these enzymes’ activity was not inhibited by 
N5-Pan. In addition, these enzymes do not allow N5-Pan as alternative substrate (33, 71). The 
inhibitory activity of N5-Pan was also shown to be ineffective against growth of P. 
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aeruginosa. In addition, when the P. aeruginosa coaX gene was expressed in E.coli strain 
DV70 containing a a temperature sensitive PanK which is inactivated at 42
0
C, the microbe 
demonstrated resistance to growth inhibition by N5-Pan at the said temperature (33). 
 
Based on the promising results of pantothenamide inhibitor studies, van Wyk and Strauss 
(2008) developed a method for parallel production of a variety of pantothenamides for 
inhibitor identification purposes. Based on the known reactivity of activated thioesters 
towards amines, they prepared S-phenyl thiopantothenate, S-phenyl thio-α-pantothenate (with 
one methylene group less in the β-alanine moiety)), and S-phenyl thiohomopantothenate 
(with one three methylene more in the β-alanine moiety) as activated precursors of 
pantothenic acid. Reaction of these compounds with a variety of amines produced a library of 
pantothenamides, 18, as products (Fig. 2.14) (66).  
 
When these analogues were tested against malaria parasites P. falciparum, the results showed 
that 18b demonstrated poor inhibitory activity against the parasites with a best inhibitor 
concentration being 53 µM, whereas 18a and 18c registered highest inhibitory capabilities, 
with the best α- and homopantothenamides inhibiting at a concentration of 4.6 and 2 µM 
respectively. However, despite demonstrating inhibitory activities against P. falciparum, 
concentration-response curves of 18a and 18c showed a significant lowering of their 
antiplasmodial activity in the presence of an increased pantothenate concentration in the 
extracellular medium. This demonstrated that the activities of these analogues were 
competitive with respect to pantothenate utilization, and that their effect was antagonized in 
the presence of increased pantothenate. Importantly, the same shift was not seen in the case 
of the normal pantothenamide series 18b. 
 
Figure 2.14: Structures of N-substituted pantothenamides with varied β-alanine moiety. 
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In the same study, it was found that 18b negatively affected growth of S aureus, with the best 
hit inhibiting at a concentration of 1.5 µM, whereas 18a and 18c were not active at 
concentrations as high as 200 µM. 
2.15 Conclusion 
As this literature review has shown, pantothenic acid analogues have a rich history in 
antibacterial and antimalarial drug discovery studies, which recently have received renewed 
interest with the rediscovery of the pantothenamides as potential antimicrobial agents. With 
the ability to inhibit all three CoA-related targets (pantothenate uptake, pantothenate 
phosphorylation and CoA utilization), such analogues definitely deserve further study.   
 
Achieving the objective of this study: Specific Aims 
The main objective of this study is the synthesis and characterization of new pantothenic acid 
analogues as potential antibacterial and antimalarial agents. Specifically, we wanted to: 
 
1. Expand the current structural diversity of normal-type pantothenamides (i.e. those 
prepared from pantothenate, see Fig. 2.14) by the addition of methyl groups in the β-
alanine moiety of pantothenate to determine if such a change will improve the 
antiplasmodial activity of these compounds. 
 
2. Prepare and test pantoyltauramides as antimicrobial agents, including the analogues of 
the best pantothenamide inhibitors identified in previous studies in our group, and 
those that showed promising inhibitory effects against avian malaria parasites in the 
studies highlighted above.   
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C h a p t e r  3 
Results and Discussion 
AIM 1: Preparing and characterizing N-substituted α- and 
β-methylpantothenamides as antimicrobial agents 
For the first aim of this study we set out to expand the structural diversity of the normal-
pantothenamides previously prepared in our group (see section 2.14) by introducing methyl 
substituents on the α- and β-carbons of the β-alanine moiety of the pantothenate molecule. 
The strategy behind this modification was to determine whether the increase of steric bulk 
would increase the biological stability of these compounds, as one possible reason for their 
poor inhibitory activity could be due to the hydrolysis of the pantothenamide amide bond. 
Such a hydrolysis reaction, which could be enzyme-catalyzed, would release pantothenate and 
the amine substituent, and would render the pantothenamide harmless. If such an analysis is 
correct, the introduction of steric bulk close to the amide carbonyl may reduce the rate of 
pantothenamide hydrolysis, and increase the potency of the compounds. However, such 
modifications could also negatively impact on the potency if they reduce the compounds’ 
binding to either the CoA biosynthetic enzymes that transform them into CoA metabolites, or 
to the actual target of inhibition. We therefore decided to prepare the α- and β-methylated 
analogues of the normal-pantothenamides that were previously found to be the best inhibitors 
of plasmodial and bacterial growth, and to test these to see if their inhibition profile is 
improved. 
 
To prepare these methylated pantothenamides, a parallel synthesis method that was previously 
developed on our group was used (66). In this method, the methylated pantothenic acids are 
prepared, and then converted to their corresponding activated thioesters. The thioesters 
subsequently undergo aminolysis by reaction with the appropriate amines to give the required 
pantothenamides (Scheme 4.1). 




Scheme 3.1: General approach for the parallel synthesis of methylated pantothenamides 
    
3.1 Parallel Synthesis of α- and β-methyl pantothenamides 
3.1.1 Synthesis of α- and β-methyl S-phenylthiopantothenate 
The synthesis of the α- and β-methyl pantothenate thioesters was performed as shown in 
scheme 3.2. Since the corresponding pantothenic acids were not commercially available, these 
were prepared first. Isoaminobutyric, 19, was condensed with pantolactone, 20, to produce α-
methyl pantothenic acid, 21, in 78% yield. Similarly, β-methyl pantothenic acid, 24, was also 
prepared by condensing 3-aminobutyric acid, 23, with 20, and was obtained in 54% yield. 
1
H 
NMR spectroscopic analysis confirmed formation of these acids.  
 
In the next step, the α- and β-methyl pantothenic acids 21 and 24 were then coupled to 
thiophenol in the presence of diphenylphosphoryl azide (DPPA) and triethylamine (Et3N) to 
obtain the corresponding S-phenyl α-methylthiopantothenate, 22, and S-phenyl β-
methylthiopantothenate, 25, in 55% and 47% yield respectively. 
1
H NMR and MS analysis 
confirmed formation of these thioesters.  
 
 

























































Scheme 3.2. Synthetic route for preparation of S-phenyl α- and β-methyl thiopantothenate esters. 
 
It is important to note that while the established reaction conditions were initially used in the 
preparation of these thioesters, the introduction of the methyl groups clearly influenced the 
reactivity of the starting materials, and therefore the yields of the reaction. However, 
optimization of the reaction conditions allowed for the successful preparation of these 
thioesters as described.  
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3.1.2 Synthesis and purification of alkyl N-substituted pantothenamides 
In order to synthesize the N-substituted α- and β-methyl pantothenamides, the activated 
thioesters 22 and 25 were subsequently reacted with a diverse group of amines in parallel. For 
the synthesis and purification of these pantothenamides the method previously developed in 




Scheme 3.3. Parallel synthesis and purification of N-substituted α- and β-methyl pantothenamides 
using S-phenyl thioesters 22 and 25 (n=2) as precursors in aminolysis reactions with m number of 
amines, producing a library with n x m members. 
 
First, the S-phenyl α- and β-methylthiopantothenates were separately subjected to aminolysis 
reactions with a variety of amines to obtain the desired corresponding pantothenamides 
(Scheme 3.4). The aminolysis reactions were performed in 96-well 2 mL deep-well plates, 
and involved incubating the thioesters in the presence of five equivalents of amine for a 
period of 3 hours at moderate temperature (30
o
C), followed by addition of 1,4-diaminobutane 
to each well. The 1,4-diaminobutane reacts with any unreacted thioester to yield N-(4-amino-
butyl) α- and β-methylpantothenamides. The pantothenamides produced were subsequently 
purified according to the established method (66). The reaction mixtures were transferred to a 
new 96-well filter plate preloaded with weakly acidic cation exchange resin, and allowed to 
Stellenbosch University  http://scholar.sun.ac.za
36 
 
elute under gravity. This allowed the resin to remove excess amine as well as any N-(4-
amino-butyl) pantothenamides produced by reaction with unreacted thioester. The resin was 
thoroughly rinsed with aqueous acetonitrile, after which the solvent and thiophenol was 
simultaneously removed from the eluents by evaporation. 
 
 
Scheme 3.4. Purification of N-substituted α- and β-methylpantothenamides produced by parallel 
aminolysis of activated thioesters. 
 
Table 3.1 shows the structures of the 20 amines (26a-t) that were used in the aminolysis of S-
phenyl α- and β-methyl thiopantothenate 22 and 25, as well as the corresponding yields of the 
N-substituted α-methylpantothenamides 27a-t, and N-substituted β-methylpantothenamides 
28a-t obtained after purification.  
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Table 3.1. Aminolysis of S-phenyl - and -methylthioesters 22 and 25 with a variety of amines (26a-
t) to form the corresponding N-substituted -methyl pantothenamides (27a-t) and N-substituted -
methyl pantothenamides (28a-t). Yields were determined by weight determination of each purified 





  % Yields    % Yields 
Amine R-group 
-Me-Pan β -Me-Pan  
Amine R-group 
-Me-Pan β -Me-Pan 
27a-j 28a-j  27k-t 28k-t 
26a  



















































The results show that we have prepared and successfully purified in parallel the N-substituted 
α- and β-methylpantothenamides 27a-t and 28a-t respectively by following a procedure 
outlined in scheme 3.4. Overall, the parallel syntheses of these pantothenamides were judged 
to have been successful since the yields of most of the purified products are above 70%, with 
only five pantothenamides (27i, 27m, 27o, 27s and 28s) that gave yields lower than this 
benchmark. Of these, four are α-methyl pantothenamides, indicating that the position of the 
methyl group on the β-alanine moiety of the pantothenate thioester definitely influences the 
reactivity of the carbonyl group, as expected. Moreover, the lowest yields of 38% (27s) and 
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51% (28s) being obtained for the products of the aminolysis with the same amine (26s), 
suggesting that it may not be as reactive or pure as anticipated.  
3.2 Inhibitory effects of N-substituted α- and β-methylpantothen-
amides against bacterial growth1 
To determine the effect of the modification of the pantothenamide backbone on the 
antibacterial potency of these compounds, we set out to test all 40 N-substituted α- and β-
methylpantothenamides against the S. aureus RN 4220 strain. Inhibition assays were 
performed at a single concentration of 200 µM methylpantothenamide as an initial screen for 
inhibitory activity. The potency of each pantothenamide was evaluated by comparing the 
growth S. aureus grown in 1% tryptone (the positive control, which showed 100% growth) to 
its growth in the same medium with the pantothenamides added. The results for the α- and β-
methyl pantothenamides are summarized in the figures 3.1 and 3.2 respectively. These show 
that in most cases both sets of pantothenamides exhibit poor inhibition of S. aureus with 
growth inhibition ranging between 10-30% at the test concentration of 200 µM.   
 
 
Figure 3.1. Growth of S. aureus in the presence of 200 µM of the α-methylpantothenamides 
27a-t. 
                                                            
1 The growth inhibition tests were performed with the assistance of Mr. Cristiano Macuamule, a PhD candidate 


























































































α-methylpantothenamides (200 µM) 
S. aureus growth inhibition by α-methyl- 
pantothenamides  





Figure 3.2: Growth of S. aureus in the presence of 200 µM of the β-methylpantothenamides 
28a-t. 
 
The inhibition results of the methylpantothenamides showing the best inhibition were 
subsequently compared to the inhibition data obtained for the normal pantothenamides 







































































































β-methylpantothenamides (200 µM) 
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A R-group % inhibition at 200 µM 
























From the the inhibition of the α-methylpantothenamides (Table 3.2) it can be seen that N-
pentyl α-methylpantothenamide (27c) and N-cyclopentyl α-methylpantothenamide (27g) 
inhibited the growth of S. aureus by only 22 and 21% respectively. Previous studies showed 
that the normal pantothenamides with the corresponding R-groups had relatively low 
antistaphylococcal activity. N-piperonyl α-methylpantothenamide (27r) is the analogue that 
shows the best growth inhibition among the α-methylpantothenamides, with a modest value of 
27%. Likewise, the corresponding normal N-piperonylpantothenamide demonstrated a 
relatively poor antibacterial activity in the previous study. The other α-
methylpantothenamides (27i, 27m, 27o, 27q, and 27s) inhibited growth of S. aureus in the 
range between 23 and 24%, whereas the corresponding normal pantothenamides had the same 
poor activities. On the other hand, α-methylpantothenamides with aliphatic R-groups, such as 
pentyl (27c), hexyl (27d) and heptyl (27e) inhibited growth of S. aureus by only 22, 14, and 
18% respectively (Fig. 3.1), although the data from the previous study showed that normal N-
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pentyl, N-hexyl, and N-heptyl pantothenamides potently inhibited the growth of S. aureus. 
Based on these results, we can conclude that the introduction of the methyl group on the α-
carbon of the β-alanine moiety of normal pantothenamide has not enhanced the anti-
staphylococcal activity of the resulting analogues, as evidenced by the poor showing of these 
analogues as potential inhibitors.  
 
Among the β-methylpantothenamides tested, five (28a, 28b, 28f, 28g, and 28h) showed better 
inhibitory activities between 30-60%, with the best analogue (28h) inhibiting S. aureus 
growth by 62% (Table 3.3). This result is in agreement with the previous inhibition results 
which showed that the N-substituted normal pantothenamide with a methylcylopropyl group 
showed improved inhibition. Similarly, the results show that N-cyclopentyl β-
methylpantothenamide (28g), and N-isobutyl β-methyl pantothenamide (28f) inhibited 
proliferation of S. aureus by 30 and 34% respectively. In the previous study it was shown that 
normal pantothenamides containing cyclopentyl and isobutyl R-groups demonstrated better 
activities against S. aureus. From the results, it can also be seen that N-propyl β-
methylpantothenamide (28a) inhibited by 43%, whereas normal propyl pantothenamide 
demonstrated activity against S. aureus with MIC value of 50 µM in the previous study. 
 







Entry R-group % inhibition at 200 µM 
28a  43 
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The data presented in table 3.3 suggests that the β-methylpantothenamides, especially 28h, 
may in fact be promising anti-staphylococcal agent. However, since the data from the 
previous study in our lab showed that normal pantothenamides with R-groups similar to the 
ones shown in table 3.3 also demonstrated remarkable activities against S. aureus, we can 
conclude that the anti-staphylococcal activities demonstrated by the β-methylpantothenamides 
is not due to the methyl group which was introduced on the β-alanine moiety of normal 
pantothenamides, but is attributed to the nature of R-groups on these analogues. We can 
therefore conclude that the β-methyl functionality has no additional effects as far as inhibitory 
activities of the pantothenamides are concerned. 
 
3.2.1 Inhibitory effects of N-substituted α- and β-methylpantotenamides 
against P. falciparum growth2 
In previous studies done in our lab, it was found that normal pantothenamides were poor 
inhibitors of P. falciparum. In fact, there was little or no inhibitory activity when most of the 
analogues were tested at a concentration of 200 µM (M. de Villiers, PhD dissertation, 2009). 
 
In the current study, α- and β-methyl pantothenamides were tested for growth inhibition of P. 
falciparum (3D7 strain). Growth assays were done at single concentrations of 200 µM to 
determine if any of the compounds gave good inhibition at this concentration. Uninfected 
erythrocytes were included to act as control (0% parasite growth). Infected red blood cells 
without any added analogues also acted as a negative control (100% parasite growth). Since 
the pantothenamides were dissolved in DMSO, inhibition by DMSO was tested as well. A 
known antimalarial, chloroquine, was included as a positive control. The results for the α- and 









                                                            
2
 The growth inhibition tests were performed with the assistance of Mr. Cristiano Macuamule, a PhD candidate 
in the Strauss group 
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Figure 3.3b. Growth inhibition of P. falciparum in the presence of 200 µM of β-
methylpantothenamides. 
The results show that the parasites registered 100% growth in DMSO, implying that DMSO 
does not have any effect on the inhibitory activities of the analogues. Parasites cultured in 
media containing chloroquine only registered 20% growth, as expected. In general, the α-
methyl pantothenamides (figure 3.3a) showed better inhibition, with the most active 
inhibitors, N-propyl α-methylpantothenamide (27a), N-butyl α-methylpantothenamide (27b) 
and N-pentyl α-methylpantothenamide (27c), N-cyclohexylmethyl α-methylpantothenamide 
(27i), N-3-methylbutyl α-methylpantothenamide (27m), inhibiting proliferation of the 
parasites by more than 80%. Other active analogues which also demonstrated promising 
activity include: N-hexyl α-methylpantothenamide (27d), N-benzyl α-methylpantothenamide 
(27o) and N-4-methoxyaminobenzyl α-methylpantothenamide (27p). These analogues 
inhibited proliferation of malaria parasites by 60%. Overall, of the twenty α-
methylpantothenamides tested, six analogues, (27e, 27f, 27j, 27n, 27r and 27s) demonstrated 
poor activity as they only registered growth inhibition of less than 50% at 200 µM. 
 
The best β-methylpantothenamide inhibitors (figure 3.3b) were N-propyl β-
methylpantothenamide (28a), N-butyl β-methylpantothenamide (28b) and N-pentyl β-
methylpantothenamide (28c), N-hexyl β-methypantothenamide (28d), N-cyclopentyl β-
methylpantothenamide (28g), and N-3-methoxybenzyl β-methylpantothenamide (28j) 
inhibiting proliferation of the parasites by more than 80%. Additionally, the analogues 28h, 
28i, 28l, 28m, 28n and 28p demonstrated some activity by inhibiting growth of malaria 
parasites by more than 50%. However, of the tested β-methylpantothenamides, compounds 
28e, 28f, 28k, 28o, 28q, 28s, and 28t showed poor inhibition (less than 50%).  
 
Comparing the antiplasmodial activities of the α- and β-methylpantothenamides, the data 
shows that methylated pantothenamides containing aliphatic R-groups such as propyl (27 and 
28a), butyl (27 and 28b), pentyl (27 and 28c), and hexyl (27 and 28d) were among the best 
active inhibitors. On the other hand, the normal pantothenamides with corresponding aliphatic 
R-groups displayed poor activities against proliferation of P. falciparum in the previous study. 
There is also an interesting trend on the poor activities of some of the methylated 
pantothenamides. For example, compounds such as 27 and 28e, 27 and 28f, 27 and 28q, and 
27 and 28s, which have similar R-groups, all show poor activity. The poor inhibitory activity 
of these analogues can therefore be attributed to the nature of these R-groups. 
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In the same study, the methylated pantothenamides which inhibited proliferation of malaria 
parasites by more than 50% were selected and subjected to a secondary screen at 50 µM. The 
results for the selected methylated pantothenamides are summarized in the figure 3.4 and 



















Figure 3.4. Growth inhibition of P. falciparum in the presence of 50 µM selected α- and β-
methylpantothenamides 
 
As can be seen from the results in figure 3.4, the majority of the selected methylated 
pantothenamides inhibited growth of malaria parasites with growth inhibition ranging 
between 50-80%. This is a clear demonstration that these analogues may be potential 
antimalarials. As summarized in table 3.4 below, certain pantothenamides such as 27d, 27k, 
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Entry R-group % inhibition at 50 µM  % inhibition at 50 µM 
a  65  78 
b  70  70 
c  72  58 
d  40  56 
g 
 
65  82 
h 
 











  46 
k O  20  NT 
m 
 
















77  34 
a
NT, not tested. 
 
Based on these results it is clear that, unlike in the case of bacteria, the antiplasmodial potency 
of the methylpantothenamides are not based on their N-substituents, but on the introduced 
methyl groups in the β-alanine moiety. These results therefore indicate that the introduction of 
the methyl groups may indeed have had the desired effect in improving the biological stability 
of the pantothenamides, and suggest that especially the N-substituted methylated 
pantothenamides deserve further investigation as these showed a definite improvement in 
their inhibition capabilities. 
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Aim 2: Preparing and characterizing N-substituted 
pantoyltauramides as antimicrobial agents 
 
Sulfonamides are a group of pharmaceutical compounds that is receiving much attention 
because of its biological activities. A large number of sulfonamides are used in clinical 
medicine among others as antibacterial, diuretics and HIV protease inhibitors (72-74). 
Additionally, some are used in the agricultural industry as herbicides and plaguicides which 
are important for protecting vines from attacks caused by insects and weeds (73, 74).  
 
According to the literature, sulfonamides have been synthesized using a variety of different 
methods, with the most general involving nucleophilic attack by ammonia or amines on 
sulfonyl chlorides in the presence of a base. However, despite the effectiveness of this 
method, it requires the availability of sulfonyl chlorides, which in the case of alkyl sulfonic 
acids may be difficult to prepare and handle. Recently, sulfonamides have been prepared from 
thiols as substrates using a H2O2-ZrCl4 reagent system which converts them into sulfonyl 
chlorides; these then act as precursor for the synthesis of these sulfonamides (73). However, 
regardless of the specific method (which often is laborious and time-consuming), they only 
allow the synthesis of sulfonamides one at a time.  
 
In an effort to develop new routes for the synthesis of pantoyltauramides as potential 
antimicrobial compounds, our approach was to develop a method that entails parallel 
synthesis and purification in a manner similar to that used to prepare the pantothenamides. 
The library of sulfonamides produced by such a method would subsequently be used for 
inhibitor screens. To the best of our knowledge, such a parallel synthetic method for the 
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Scheme 3.5. Proposed strategy for the parallel synthesis of pantoyltauramides 
 
In the process of developing a method for the parallel synthesis of pantoyltauramides, we 
realized there were several challenges that could hamper our progress in the synthesis of these 
compounds. The first challenge was the choice of protecting groups for the 2´- and 4´-OHs of 
the pantoate moiety, since these functional groups would likely interfere in the activation of 
the sulfonic acid or preparation of the sulfonamide.  The second challenge was related to the 
choice of activating group for the sulfonic acid (scheme 3.5). In an attempt to address these 
challenges, we set out to investigate a number of reactions that would involve different 
protecting and activating groups in our quest to develop this method. Our strategy was to use 
pantoylcysteamine or pantoyltaurine as substrates, and to determine if these could be used for 
the successful development of the proposed method. 
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3.3.1 Attempt 1: Synthesis of pantoyltauramides from pantoylcysteamine 
via the corresponding sulfonyl chloride 
Our first attempt at the synthesis of the pantoyltauramides involved using pantoylcysteamine 



























































Scheme 3.6: Proposed route for the synthesis of PMB-protected pantoyltaurines from 
pantoylcysteamine 
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Pantoylcysteamine 30 was prepared by condensing pantolactone, 20 with cysteamine, 29, 
which yielded 30 in 75% yields. The structure of the product was confirmed by 
1
H NMR 
analysis. For protection of the 1,3-diol, we first attempted to use a p-methoxybenzyl (PMB) 
acetal as a protecting group. The protection reaction was performed in the presence of 10-
camphor sulfonic acid (CSA) as a catalyst to obtain the protected thiol, 31, in 55% yield. The 
1
H NMR spectroscopic analysis of the protected molecule showed that the product was 
successfully prepared. 
 
After successful introduction of the protecting group, we set out to investigate the conversion 
of the thiol to a sulfonyl chloride as an activating group. Such a conversion was first used by 
Prakash et al (75) in a study in which he utilized the oxidizing properties of TMS-Cl/KNO3 
reagent system to convert thiols to sulfonyl chlorides. The reaction was performed as 
described (75) by dissolving the protected thiol in CH2Cl2, and subjecting it to oxidation by 
TMS-Cl/KNO3. Immediately after adding the reagent to the reaction mixture, we observed the 
formation of a viscous suspension. In addition, even after 24 hour of stirring, the reagent did 
not completely dissolve. 
1
H NMR spectroscopic analysis showed that the desired sulfonyl 
chloride, 32, was not obtained. Our results are in contradiction to the literature results (75), 
because by using the similar method, Prakash et al obtained the desired products within 2-3 
hours of reaction. Our results showed that this reagent was not suitable for the oxidation and 
activation of pantoyltaurine protected with a PMB group. 
 
3.3.2 Attempt 2: Synthesis of pantoyltauramides from pantoylcysteamine 
via the corresponding sulfonyl chlorides and pentafluorophenol ester 
In a second effort to develop a method for parallel synthesis of sulfonamides, we decided to 
explore the viability of converting pantoyltaurine directly to the sulfonyl chloride and 
subsequently to the pentafluorophenol (PFP) ester, without protection. Such (PFP) could then 
be used in aminolysis reactions to produce sulfonamides. Our aim was to investigate the 
applicability of utilizing pentafluorophenol as an activating group. First, we used a procedure 
developed by Bahrami et al (73) which utilizes H2O2 in combination with SOCl2 for direct 
conversion of thiols to the corresponding sulfonyl chlorides through oxidative chlorination 
(Scheme 3.7). 
 




Scheme 3.7. Proposed synthetic route leading to formation of pantoyltaurines  from the corresponding 
pentafluorophenol esters. 
 
A reaction mixture consisting of pantoylcysteamine 30, H2O2 (30%), and SOCl2 was stirred in 
MeCN at 25
o
C for 5 minutes, according to the literature (73). After completion of the reaction 
time, however, we noticed that the thiol did not properly dissolve and that a colloidal 
suspension formed. According to TLC analysis, there was nothing shown on the TLC plate as 
an indication of the formation of product. We attempted to add a solution of 
pentafluorophenol in Et3N to the colloidal suspension. However, only a viscous suspension 
resulted. Spectroscopic analysis by 
1
H NMR did not show the formation of any of the desired 
products. From these results, it is clear that failure to protect the 1,3-diol of pantoylcysteamine 
may have detrimental consequences in the reactivity of the compound. According to the 
literature procedure, sulfonyl chlorides were obtained within 2 minutes of the reaction. 
However, in their case only aromatic thiols that had no multiple hydroxyl functionalities were 
used. We utilized an aliphatic thiol with free hydroxyl groups as a starting material, so we 
suspect that the most likely problem is the possibility of SOCl2 reacting with the unprotected 
alcohols. Consequently, similar chemoselectivity was clearly not achieved.    
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3.3.3 Attempt 3: Synthesis of pantoyltauramides by activation of 
pantoyltaurine 
A third strategy involved attempting to synthesize sulfonamides from pantoyltaurine by 
following the synthetic route depicted in the scheme 3.8. First, pantoyltaurine 40 was 
synthesized using taurine as a starting material. Taurine, 37, was dissolved in one equivalent 
NaOH (1M) to produce the tauryl sodium salt 38, which was then condensed with 
pantolactone 20 upon heating to produce pantoyltaurine sodium salt 39. The salt produced 




 to produce (R)-
pantoyltaurine 40 in 75% yield. 
1
H NMR analysis confirmed the formation of this product.  
 




Scheme 3.8. Proposed route for the synthesis of pantoyltauramides from pantoyltaurine. 
 
To protect the 1,3-diol moiety  of pantoyltaurine, we decided to use 2,2-dimethoxy propane to 
convert this group to the dimethyl acetal 41. However, when the reaction was complete, 
1
H 
NMR spectroscopic analysis of the reaction mixture showed that instead of the expected 
product, spectral data correlated well with that of the starting material, indicating that the 
protection reaction was not successful. 




We also attempted to protect the 1,3-diol groups of commercially obtained (R,S)-
pantoyltaurine sodium salt by using acetic anhydride to convert these to the corresponding 
acetates. The protection reaction (scheme 3.9) was performed by suspending the 
pantoyltaurine sodium salt in acetic anhydride with a catalytic amount of iodine (I2) and then 
stirring the mixture at 0
o
C for 2 hours followed by stirring at room temperature for 18 hours 
with subsequent removal of solvent in vacuo.  
 
 
Scheme 3.9. Proposed protection of the 1,3-diol of pantoyltaurine sodium salt using acetic 
anhydride. 
 
However, during the course of the reaction, we noticed that pantoyltaurine sodium salt did not 
properly dissolve in acetic anhydride; much of the salt remained undissolved after 18 hours of 
stirring. Spectroscopic analysis of the product by 
1
H NMR showed that acetylation of 
pantoyltaurine sodium salt did take place but only in low conversion. 
 
The ability of trifluoroacetic anhydride to introduce protecting groups was also investigated. 
In this strategy, we again attempted to protect commercially obtained pantoyltaurine sodium 
salt. The protection was conducted by adding trifluoroacetic anhydride drop wise over 5 
minutes to a stirred suspension of pantoyltaurine sodium salt in dry THF (Scheme 3.10). 
 
 
Scheme 3.10. Proposed protection of 1, 3-dihydroxyl groups of pantoyltaurine sodium salt using 
trifluoroacetic anhydride. 
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Upon addition of trifluoroacetic anhydride the reaction was stirred for over 24 hours; 
however, the pantoyltaurine sodium salt again did not dissolve, and the procedure was 
abandoned. 
 
The attempted synthesis of sulfonamides using methods of our own design proved to be 
unsuccessful in our hands. We therefore decided to revisit the methods that were originally 
reported for the preparation of pantoyltaurines in the first studies aimed at investigating these 
important compounds as antiplasmodial agents. 
  
3.3.4 Synthesis of pantoyltauramides by modification of taurine:  original 
synthetic methods 
In the original studies of pantoyltauramide by Winterbottom and co-workers  (51), a reversed 
strategy was used for the preparation of these compounds. Instead of activating and reacting 
the sulfonic acid group of pantoyltaurine with amines to prepare the pantoyltauramides, they 
first prepared the tauramides and subsequently reacted these with pantolactone to give the 
desired products (Scheme 3.11). They achieved this by using phthalic anhydride to protect the 
free amine of taurine, followed by its reaction with thionyl chloride. The resulting sulfonyl 
chloride was subsequently reacted with a variety of amines to obtain phthalimide-protected 
tauramides. Deprotection with hydrazine hydrate (N2H4) released the amino group of the 
tauramide 49 (76), which was finally condensed with pantolactone to produce the desired 
sulfonamides.  
 




Scheme 3.11. Synthetic route used for the first and original synthesis of 36. 
 
Based on the apparent success of this method, we decided to investigate it for the synthesis of 
pantoyltauramides in our case. However, we decided to employ an amine protecting group 
other than phthalimide since its deprotection requires hydrazine, which is highly toxic and 
dangerous, and since such a procedure would not be suitable for parallel synthesis. Also, we 
wanted to investigate other methods for the activation of the sulfonic acid.  
 
In view of this background, we decided to explore other published methods used in the 
synthesis of tauramides, and to apply these in a modification of the original pantoyltauramide 
synthesis. We therefore attempted to use a method which involves using benzyl carbamates 
(Cbz) and sulfonyl fluorides as protecting and activating groups respectively. 
 
3.3.5 Attempt 4: Synthesis of pantoyltauramides by modification of taurine:  
using modified protection and activation strategies 
3.3.5.1 Protection and activation of taurine 
The modified strategy for the synthesis of protected and activated tauramides (Scheme 3.12) 
relied on published methods. A method for the protection of the amino group of taurine 37 
using Cbz-Cl was developed by Brouwer et al in 2000 (77). We attempted to use this method 
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in our effort to synthesize tauramides 49 from taurine. With slight modification to the method, 
the protection of taurine with Cbz-Cl was conducted as follows: taurine was dissolved in 
aqueous NaOH (1 M) followed by addition of a solution of Cbz-Cl in dioxane with stirring for 
1 hour (Scheme 3.12). The reaction mixture was then extracted with EtOAc to get rid of 
unreacted Cbz-Cl, followed by evaporation of solvent in vacuo. While the literature procedure 
made use of P2O5 to dry the crude sodium sulfonate salt 50, we instead freeze dried the 
product, which was obtained in 90% yield. 
 
 
Scheme 3.12.  Protection of taurine with Cbz-Cl, followed by activation of the sulfonic acid by 
reaction with DAST to form the sulfonyl fluoride. 
 
In our effort to activate the sulfonate salt prepared above for aminolysis, we explored the 
practicability of using diethylaminosulfur trifluoride (DAST) as an activation agent , as 
described in the literature (78). With a minor modification to the method, a solution of DAST 
was added to stirred slurry of the sodium sulfonate 50 in CH2Cl2 at 0
o
C under a N2 
environment. Product formation was followed by TLC analysis. The product was obtained 
after stirring for 2 hours at 0
o
C, followed by solvent evaporation and purification by flash 
chromatography. The resulting fluoride 51 (Scheme 3.12) was characterized by 
1
H NMR and 
19
F NMR to verify its structure. 
19
F NMR spectral data showed the presence of a fluorine peak 
at 56.90 ppm. This shows that the fluorination of 50 was successfully achieved with the 
product 51 being obtained in good isolated yield of 44%. 
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3.3.5.2 Synthesis of Cbz-tauramides by aminolysis of Cbz-tauryl fluoride 
In our attempt to subject the Cbz-tauryl fluoride 51 to aminolysis, we again used a method 
available in the literature (79). Conversion of Cbz-tauryl fluoride to Cbz-tauramides 52 was 
done by reaction of a variety of amines with the fluoride dissolved in CH2Cl2, at 50ºC 
(Scheme 3.13).  
 
  
Scheme 3.13. Reaction of sulfonyl fluoride with various amines 
 
The formation of product was monitored by TLC, 
1
H NMR, as well as 
19
F NMR. In the case 
of 
19
F NMR spectroscopic analysis, the formed products failed to show a fluorine peak, as 
expected. In reactions where no product was obtained, 
1
H NMR spectroscopic analysis of the 
reaction mixtures did not show the formation of any structures that correspond with the 
expected products. In addition, 
19
F NMR spectroscopic analysis showed the presence of 
fluorine peaks, showing the aminolysis reaction did not take place in these reactions.  
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Table 3.6. Cbz-tauramides and their corresponding yields  




























































The results of the aminolysis reaction are shown in the table 3.6, and show that the Cbz-
tauramides were obtained in excellent yields and with high purity in some reactions, (52b, 
52c, 52d, 52n, 52h, 52o and 52q), while no product was formed in other reactions 52u, 52v, 
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52t and 52x). Aromatic amines (anilines) with either electron-withdrawing or electron-
donating substituents (Table 3.6, entries 52u-52x) did not react very well and did not give 
corresponding Cbz-tauramides. However, all aliphatic amines, even those with aromatic side 
chains, produced the corresponding Cbz-tauramides in good yields (Table 3.6, entries 52b, 
52c, 52d, 52n, 52h, 52o and 52q). This results show that Cbz-protected tauryl fluorides are 
ideal precursors for the parallel synthesis of tauramides. 
 
3.3.5.3 Synthesis of tauramides by deprotection of the Cbz-tauramides 
Upon realizing successful aminolysis, we then attempted to cleave off Cbz-group from Cbz-
tauramides through catalytic transfer hydrogenation (Scheme 3.14). 
 
 
Scheme 3.14. Deprotection of 52b, 52c, 52d, 52n, 52h, 52o and 52q (table 3.6) by catalytic 
hydrogenation 
 
First, we attempted to cleave off Cbz-Cl group from Cbz-tauramides 52b, 52c, 52d, 52n, 52h, 
52o and 52q (Table 3.6) by hydrogenation under N2 environment using 10% Pd-black with 
ammonium formate in methanol acting as a donor of hydrogen. However, spectroscopic 
analysis of the hydrogenation products by 
1
H NMR analysis showed that spectral data 
obtained did not correspond with the structures of the expected tauramides. Instead, it 
corresponded well with the structure of the starting material, the Cbz-tauramides. This shows 
that the catalytic transfer hydrogenation was not successful. This can be attributed to either 
the ammonium formate not acting as hydrogen donor as expected, or that the palladium 
catalyst was not effective under these conditions. 
 
Next we attempted to remove the Cbz-group from Cbz-tauramides by refluxing the latter 
using concentrated HCl in the presence of methanol (Scheme 3.15). However, 
1
H NMR  
spectroscopic analysis showed that this deprotection did not work for compounds 52b, 52d, 
52h and 52o (Table 3.6), but  was successful in the case of three compounds 52c, 52n, and 
52q (Table 3.6) with high isolated yields of about 72, 89 and 70% respectively.   




Scheme 3.15. Deprotection of 52b, 52c, 52d, 52n, 52h, 52o and 52q (table 3.6), using conc. HCl in 
MeOH. 
 
3.3.5.4 Synthesis of pantoyltauramides from tauramides 
With the free tauramides 49 in hand, the desired pantoyltauramides 36 could be prepared by 



















Scheme 3.16: Coupling of tauramides to pantolactone to form pantoyltauramides 
 
The pantoyltauramides 36 were prepared by adding pantolactone 20 (3 equiv) and Et3N (3 
equiv) to a solution of tauramides 49 in ethanol. The reaction was allowed to stir under reflux 
for 7 hours, after which the solvent was evaporated, and the resulting pantoyltauramide was 
purified by flash chromatography (1:4 EtoAC: Hexane to 2:1 EtoAC: Hexane to obtain 36. 
Spectroscopic analysis of 36 by 
1
H NMR showed that N-pentyl pantoyltauramide (36c, table 
3.7) was pure as demonstrated by its clean 
1
H NMR spectrum. However, spectral data of N-2-
(ethylthio)ethyl pantoyltauramide 36q, (table 3.7), and phenethyl pantoyltauramide 36n (table 
3.7) showed that these two compounds contained some residual triethyl amine as signified by 
the presence of  peaks at 1.35 and 3.2 ppm respectively. This was surprising, since these 
pantoyltauramides were subjected to several purification processes by varying the ratio of 
EtoAC to hexane, including dissolving of the pantoyltauramides in water with subsequent 
lyophilisation in order to get rid of the triethylamine. 
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Table 3.7: Pantoyltauramides and corresponding yields 















3.3.6 Conclusion  
Our attempts to develop a method for parallel synthesis and purification of pantoyltauramides 
proved to be unsuccessful. However, we have managed to synthesize pantoyltauramides by 
using methods described in the literature. Overall, we failed to synthesize as many 
pantoyltauramides as possible due to a number of difficulties we encountered in the synthetic 
process. For example, in the process of cleaving off Cbz-group from Cbz-tauramides, the 
procedure entailed refluxing the Cbz-tauramides in concentrated HCl, which proved to be 
incompatible with some amine functionalities. While the Cbz-groups could most probably 
have successfully been removed by hydrogenation in some of these cases, such a method 
would not be amenable to parallel synthesis. It will therefore be important to investigate other 
amine protecting groups in future work.  
3.4 Inhibitory effects of N-substituted pantoyltauramides against P. 
falciparum 
In studies performed in 1940’s, all the pantoyltauramides prepared at that time were tested for 
antimalarial activity in birds. Findings showed that N-(4-chlorophenyl) pantoyltauramide 
demonstrated four times higher activity than quinine. 
 
In this study, the three pantoyltauramides 36c, 36q and 36n were tested for antiplasmodial 
activities against P. falciparum.  The results show that at a concentration of 200 µM, the 
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pantoyltauramides demonstrated very good activities, inhibiting the proliferation of P. 
falciparum by between 67 and 78%.  
 
Table 3.8. Aantiplasmodial activity of pantoyltauramides at 200 µM. 
 
















Comparing the activities of pantoyltauramides with that of N-substituted pantothenamides, it 
can be seen that the former demonstrated better inhibition of proliferation of the malaria 
parasites than the latter. The pantoyltauramides seem to be promising antimalarial agents 
considering the fact that of all the analogues tested against P. falciparum in this study, the 
pantoyltauramides showed the best inhibitory activity. Analyzing the results, it also seems as 
if certain R-groups give the best the inhibitory characteristics. For example, the N-pentyl 
substituent imparted good inhibitory characteristics to nearly all the pantothenate analogues in 
which it occurs.  Specifically, of all the alkyl N-substituted pantothenamides tested against P. 
falciparum, the N-pentyl α-methyl pentylpantothenamide 27c showed the best activity, 
inhibiting the proliferation of parasites by 65%. Likewise, N-pentyl pantoyltauramide 36c 
inhibited the growth of P. falciparum by 78% in vitro. This is the best activity of all the 
analogues tested in this study.   
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3.5 Conclusion  
The results of this study on modified pantothenamides indicate that these compounds have a 
very different activity profile when acting against bacteria compared to malaria parasites. The 
results show that the methylated pantothenamides do not exhibit increased activity on S. 
aureus compared to previous studies. This observation indicates that the added methyl 
functionalities on the β-alanine moiety did not enhance the activities of these analogues in 
these bacteria. In contrast, the series of α-methylpantothenamides did show improved 
antiplasmodial activity compared to the previous study’s results. This indicates that especially 
α-methylation of selected pantothenamides may increase the potency of these compounds 
against the proliferation of P. falciparum. The selected pantoyltauramides that were prepared 
and synthesized also showed good inhibition. This is encouraging, as it shows that both the 
methyl functionality introduced on the β-alanine moiety, as well as the sulfonamide, has 
impacted positively on the inhibitory activities of these analogues, possibly by increasing 
their biological stability. It will be important to follow up on these initial results in future 
work, particularly by determining MIC values for the most promising inhibitors. It will also 
be important to determine if the inhibitory effect of these compounds are reduced in the 
presence of pantothenate, to establish if they will be effective in vivo. 
 
  





Materials and methods 
All chemicals used in the synthesis of pantothenamides and sulfonamides were purchased 
from Sigma-Aldrich, Merck, or Acros Organics. The resin and silica used in purification 
processes were purchased from Sigma-Aldrich. All solvents used in the preparation and 
purification of these compounds were CHROMASOLV HPLC grade solvents purchased 
from Sigma-Aldrich. Polypropylene 2 mL 96-well filter plates purchased from NUNC were 
used during aminolysis reactions. AcroPrep 96-well deep-well filter pates obtained from Pall 
Life Sciences were used during filtration of pantothenamides for purification purposes. 
Polypropylene cluster tubes (Corning) were used in yield determination. Solvent from deep-
well plates was evaporated on a Labconco Centrivap concentrator. SYBR green for 
fluorescence studies as well as Gentamycin and Albumax II for cell culturing were purchased 
from Invitrogen. Flat-bottomed 96-well cell culture plates from NUNC were used for growth 
assays as well as fluorescent measurement. All NMR analyses were performed on Varian 
INOVA instruments (300 MHz, 400 MHz, and 600 MHz) at the Central Analytical Facility 
(CAF) at Stellenbosch University. All LC-ESI-MS analyses were also done at CAF using a 
Waters 2690 Separations Module with a Waters 996 Photodiode Array Detector for LC 
separations, followed by mass analysis on a Waters Micromass Quattro mass spectrometer. 
4.1 Synthetic preparation of α- and β-methyl pantothenate thioesters 
4.1.1 S-Phenyl α-methylthiopantothenate (22) 
4.1.1.1 α-Methylpantothenic acid (21)              













99                                                             
D,L-3-amino isobutyric acid (0.50 g; 4.8 mmol) was dissolved in 1M NaOH (4.8 mL) and the 
solution was freeze dried. Pantolactone (0.70 g; 5.28 mmol) was added to the resulting white 
salt and the mixture was heated under nitrogen for 17 hours at 130
o
C. The resulting sticky oil 
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was dissolved in water and loaded onto a column of Amberlite IR-120 (H
+
-form) ion 
exchange resin. The free α-methyl pantothenic acid was eluted with deionised water, and then 
lyophilized. The resulting residue was purified by flash chromatography (silica gel; ethyl 
acetate/methanol/water/acetonitrile 5:2:1:1) to remove unreacted pantolactone and amine to 
give the pure acid 21 as a sticky oil. (0.8 g; 70%). 
1
H NMR (400 MHz; D2O; 25
o
C):  δ 0.892 
(3H, s, -CH3[9]), 0.925 (3H, s, -CH3[9]), 1.21 (3H, s, -CH3[8]), 2.76 (1H, m, -CH-[7]), 3.39 
(1H, s, -CH[1]), 3.42 (1H, s, -CH[1]), 3.52 (1H, s, -CH-[6]), 3.55 (1H, s, -CH-[6]), and 4.01 
(1H, br s, -CH-[3]). 
 
4.1.1.2 S-Phenyl α-methylthiopantothenate (22)     




















        
The acid 18 (0.80 g; 3.4 mmol) was dissolved in 3.4 mL DMF, followed by addition of 
diphenylphosphoryl azide (1.3 mL; 6.12 mmol) and thiophenol (0.42 mL; 4.08 mmol). The 
reaction mixture was cooled to 0
o
C, followed by addition of triethylamine (0.854 ml; 6.12 
mmol). The reaction mixture was stirred at 0
o
C for 10 minutes, followed by stirring at room 
temperature for 3 hours. Ethyl acetate (50 ml) was added to the reaction mixture, followed by 
washing with 5% citric acid (3×10 ml), 1M NaHCO3 (3×10 ml), and saturated NaCl solution 
(2×10 ml). The organic layer was dried over Na2SO4 followed by removal of the solvent in 
vacuo using a rotary evaporator. The resulting residue was purified by flash chromatography 
(silica gel; ethyl acetate/hexane 2:1 to 4:1) to give 22 as a sticky oil (0.60 g; 55%). 
1
H NMR 
(600 MHz; CDCl3; 25
o
C):  δ 0.92 (3H, s, -CH3[11]), 1.0 (3H, s, -CH3[11]), 1.29 (3H, d, J 
6.98, -CH3[8]), 3.43-3.56 (4H, m, -CH2-[1+6]), 3.1 (1H, m, -CH-[7]), 4.05 (1H, s, -CH-[3]), 
7.1 (1H, br s, -NH-[5]), and 7.4 (5H, m, arom.[10]);  
13
C NMR (300 MHz; CDCl3; 25
o
C): δ 
15.0, 19.8, 22.0, 40.0, 42.5, 48.2, 78.0, 121.5, 128.0, 130.0, 135.2, 174.8, and 202.5; ESI-MS: 
m/z [M-H]
-
 calcd for C16H22NO4S: 324.13; found 324.1 
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4.1.2 S-Phenyl β-methylthiopantothenate (25)  
4.1.2.1 β-Methylpantothenic acid (24)     
  
The synthesis, workup and purification were performed as for 21, using (R/S)-3-
Aminobutyric acid (0.50 g; 4.8 mmol) as starting material. The pure acid 24 was obtained as 
a sticky oil (0.6 g; 54%). 
1
H NMR (400 MHz; D2O; 25
o
C): δ 0.91 (3H, s, -CH3[9]), 0.96 (3H, 
s, -CH3[9]), 1.23 (3H, s, -CH3[7]), 2.5 (2H, t, J 6.5, -CH2-[8]), 3.4 (2H, d, -CH2-[1]), 3.53 
(1H, d, J 10.46, -CH-[6]), 3.97 (1H, s, -CH-[3]) and 4.3 (1H, br s, -NH-[5]). 
 
4.1.2.2 S-Phenyl β-methylthiopantothenate (25)  
 
The synthesis, workup and purification were performed as for 22, using 24 (0.60 g; 2.6 
mmol) as starting material. The product 25 was obtained as a sticky oil (0.40 g, 47%). 
1
H 
NMR (300 MHz; CDCl3; 25
o
C): δ  0.9 (3H, s, -CH3[11]), 1.0 (3H, s, -CH3[11]), 1.3 (3H, m, -
CH3[7]), 2.86-2.91 (2H, m, -CH2-[8]), 3.5 (2H, m, -CH2-[1]), 3.99 (1H, d, J 4.7, -CH-[3]), 4.4 
(1H, s, -CH-[6]), 7.1 (1H, br s, -NH-[5]) and 7.4 (5H, m, arom.[10]); 
13
C NMR (400 MHz; 
CDCl3; 25
o
C); δ 20.2, 22.8, 40.1, 43.5, 49.0, 71.0, 78.0, 78.2, 121.5, 128.1, 132.2, 135.1, 
174.3, and 197.0; ESI-MS: m/z [M+H]
+
 calcd for C16H24NO4S: 326.13; found 326.0.  
4.2 Parallel synthesis and purification of α- and β-methylpantothen-
amides 
4.2.1 General procedure 
The thioesters 22 and 25 prepared above were subjected to parallel aminolysis using 20 
different amines (Scheme 4.1), followed by parallel purification. The procedure was executed 
according to an established method (66).  




Scheme 4.1: Aminolysis of S-phenyl methylpantothenate esters using various amines. 
 
The aminolysis reactions were performed by using stock solutions of the thioesters (prepared 
in 40% aqueous acetonitrile) and amines (prepared in 100% acetonitrile).  Reactions were 
performed in 2 mL 96-well deep-well plates by addition of the amine (100 mM final 
concentration, 5 eq.) followed by addition of the thioester (20 mM final concentration, 1 eq.)  
The negative control reaction contained no amine. Each well had a final reaction volume of 1 
mL. The deep-well plate was then capped and placed in an incubator with vigorous shaking 
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4.2.2 Purification method  
After 3 hours, 1,4-diaminobutane (100 µL; 550 mM) was added to the reaction mixtures in 
each well. The mixtures were incubated with shaking for 1 hour at 30
o
C, after which they 
were loaded onto pre-washed Amberlite IRC-86 weak cation exchange resin (300 mg dry 
weight per well) loaded in a 1 mL AcroPrep 96-well filter plate. The resin was allowed to 
elute under gravity, followed by washing it twice with 300 µL 40% aqueous acetonitrile. The 
combined eluates were dried overnight on a Centrivap concentrator under reduced pressure. 
After drying, the resin was washed again with another 1200 µL 40% aqueous acetonitrile and 
the collected eluates were added to the dried residues. The resulting solutions were 
transferred to individual pre-weighed 96-well cluster tubes and dried for another 3 days by 
centrifugal concentration to remove all solvent and thiophenol present in the product 
mixtures. After the final drying process, the cluster tubes containing the dried products were 
weighed again individually to establish the final yield of each product. 
 
N-Propyl β-methylpantothenamide (28a) 
 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 0.9 (3H, t, J 2.16, -CH3[13]), 0.95 (3H, s, -CH3[14]), 
1.0 (3H, s, -CH3[14]), 1.3 (3H, m, -CH3[7]), 1.52 (2H, m, -CH2-[12]), 2.5 (2H, m, -CH2-[8]), 
3.2 (2H, m, -CH2-[11]), 3.5 (2H, m, -CH2-[1]), 4.0 (1H, s, -CH-[3]), 4.4 (1H, br s, -CH-[6]), 
6.1 (1H, br s, -NH-[10]) and 7.5 (1H, br s, -NH-[5]). 
 
N-Butyl β-methylpantothenamide (28b) 
 
1
H NMR (300 MHz, CDCl3; 25
o
C): δ 0.9 (3H, t, J 3.42, -CH3[14]), 0.99 (3H, s, -CH3[15]), 
1.02 (3H, s, -CH3[15]), 1.25 (3H, m, -CH3[7]), 1.35 (2H, m, -CH2-[13]), 1.5 (2H, m, -CH2-
[12]), 2.5 (2H, m, -CH2-[8], 3.25 (2H, m, -CH2-[11]), 3.5 (2H, s, -CH2-[1]), 4.0 (1H, s, -CH-
[6]), 4.30 (1H, br s. –CH-[3]), 6.0 (1H, br s, -NH-[10]) and 7.5 (1H, br s, -NH-[5]). 
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N-Pentyl β-methylpantothenamide (28c) 
 
1
H NMR (300 MHz; CDCl3; 25oC): δ 0.85 (3H, m, -CH3[15]), 0.99 (3H, s, -CH3[16]), 1.01 
(3H, s, -CH3[16]), 1.23-1.33 (3H, m, -CH3-[7]), 1.23-1.33 (4H, m, -CH2-[13+14]), 1.48 (2H, 
m, -CH2-[12]), 2.3-2.45 (2H, m, -CH2-[8]), 3.4 (2H, m, -CH2-[11]), 3.5 (2H, m, -CH2-[1]), 
4.0 (1H, s, -CH-[6]), 4.3 (1H, br s, -CH-[3]), 6.0 (1H, br s, -NH-[10]) and 7.5 (1H, br s, -NH-
[5]). 
 
N-Isobutyl β-methylpantothenamide (28f) 
 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 0.89 (3H, t, -CH3[13]), 0.9 (3H, s, -CH3[14]), 0.92 (3H, 
t, -CH3[13]), 1.0 (3H, s, -CH3[14]), 1.23-1.27 (3H, m, -CH3[7]), 2.5 (2H, m, -CH2-[8]), 2.62 
(1H, br s, -CH-[12]), 2.98-3.13 (2H, m, -CH2-[11]), 3.5 (2H, m, -CH2-[1]), 4.0 (1H, s, -CH-
[6]), 4.4 (1H, br s, -CH-[3]), 6.0 (1H, br s, -NH-[10]) and 7.5 (1H, br s, -NH-[5]).   
 
N-Cyclopentyl β-methylpantothenamide (28g) 
 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 0.96 (3H, s, -CH3[14]), 1.02 (3H, s, -CH3[14]), 1.25 
(3H, m, -CH3[7]), 1.32-1.40 (2H, m, -CH-[13]), 1.93-1.96 (2H, m, -CH-[12]), 2.4 (2H, m, -
CH2-[8]), 3.5 (2H, m, -CH2-[1]), 4.0 (1H, s, -CH-[11]), 4.2 (1H, br s, -CH-[6]), 4.35 (1H, br 
s, -CH-[3]), 5.9 (1H, br s, -NH-[10]) and 7.5 (1H, br s, -NH-[5]).  
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N-Cyclopropanemethyl β-methylpantothenamide (28h) 
 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 0.2 (2H, m, -CH[13]), 0.5 (1H, m, -CH-[12]), 0.96 (3H, 
s, -CH3[14]), 1.05 (3H, s, -CH3[14]), 1.3 (3H, m, -CH3[7]), 2.5 (2H, m, -CH2-[8]), 3.1 (2H, 
m, -CH2-[11]), 3.5 (2H, m, -CH2-[1]), 4.0 (1H, s, -CH-[6]), 4.35 (1H, br s, -CH-[3]), 6.0 (1H, 
br s, -NH-[10]), and 7.5 (1H, br s, -NH-[5]).  
 
N-Cyclohexanemethyl β-methylpantothenamide (28i) 
 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 0.92 (3H, s, -CH3[15]), 0.92 (3H, s, -CH3[15]), 0.99 
(3H, t, J 6.04, -CH3[7]), 1.15-1.25 (6H, m, -CH2-[14]), 1.5 (4H, br s, -CH2-[13]), 2.4 (1H, s, -
CH-[12]), 2.5 (2H, m, -CH2-[8]), 3.1 (2H, m, -CH2-[11]), 3.5 (2H, m, -CH2-[1]), 4.0 (1H, s, -
CH-[6]), 4.3 (1H, br s, -CH-[3]), 6.0 (1H, br s, -NH-[10]) and 7.5 (1H, br s, -NH-[5]). 
 
N-2-(Ethylthio)ethyl β-methylpantothenamide (28q) 
 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 0.98 (3H, s, -CH3[15]), 1.01 (3H, s, -CH3[14]), 1.22-
1.27 (6H, m, -CH3[7+14]), 2.5 (4H, m, -CH2-[8+13]), 2.7 (2H, m, -CH2-[12]), 3.4 (2H, m, -
CH2-[1]), 3.5 (2H, m, -CH2-[11]),  4.35 (1H, br s, -CH-[3]), 6.4 (1H, br s, -NH-[10]) and 7.4 
(1H, br s, -NH-[5]). 
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4.3 Synthetic preparation of pantoyltauramides 
4.3.1 Synthesis and activation of N-carbobenzoxy taurine 
N-Carbobenzoxy taurine sodium salt (50)  
 
The synthesis was performed according to a method by Brouwer et al (77, 80). Taurine (4.0 
g, 32 mmol) was dissolved in 1M NaOH (32 mL). A solution of benzyl chloroformate 
(CbzCl) (7 mL, 48 mmol) in dioxane (42 mL) was added, followed by addition of a further 
portion of 1M NaOH (1M, 48 mL). The reaction mixture was stirred for 1 hour, and extracted 
with acetyl acetate (2×125 mL) to remove unreacted CbzCl. The aqueous layer was then 
concentrated, followed by sequential co-evaporation with toluene (100 mL), ethanol (100 
mL), and dichloromethane (3×100 mL). The crude product was lyophilized and subsequently 
used in the next step without further purification. 
 
N-Carbobenzoxy tauryl fluoride (Cbz-tauryl fluoride, 51)  
 
The synthesis was performed by modification of an established method (78). To a stirred 
slurry of 50 (0.5 g, 1.78 mmol) in CH2Cl2 (20 mL) was added a solution of 
(diethylamino)sulphur trifluoride (DAST) (0.585 ml, 4.45 mmol). The reaction mixture was 
stirred at 0
o
C for 2 hours, with product formation being monitored by TLC (10% MeOH/ 
CH2Cl2), and 
19
F NMR in CDCl3. Upon completion of the reaction the solvent was removed 
in vacuo by rotary evaporation, followed by purification using flash chromatography (silica 
gel; CH2Cl2/Hexane 1:1 to 3:1) to give 51 as a yellow powder (0.22 g, 44%). 
1
H NMR (300 
MHz; CDCl3;  25
o
C): δ 3.64 (2H, m, -CH2-[5]), 3.74 (2H, m, -CH2-[6], 5.13 (2H, s, -CH2-[2], 
5.32 (1H, br s, -NH-[4] and δ 7.35 (5H, s, arom.[1]. 
19
F NMR (300 MHz; CDCl3): δ 56.9. 
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4.3.2 Synthesis of N-carbobenzoxy N´-substituted tauramides 
 
General method 
The N-carbobenzoxy N´-substituted tauramides 52 were synthesized according to a method 
described by Toulgoat et al (79). To a solution of 51 (0.38 mmol for 52b and 52n, 1.22 mmol 
for 52c, 1.15 mmol for 52d, 0.84 mmol for 52h, 1 mmol for 52o, and 0.69 mmol for 52q) in 
DCM (3 mL) was added the appropriate amine (5 eq.) at room temperature under nitrogen. 
The reaction mixture was stirred at 50
o
C for 20 hours with product formation being 
monitored by TLC and 
19
F NMR (disappearance of fluorine peak). The reaction mixture was 
cooled to room temperature, after which 10% aqueous HCl was added. The aqueous phase 
was extracted with CH2Cl2, followed by drying of the organic layer over MgSO4, filtration 
and rotary evaporation of the solvent in vacuo to obtain the respective product. The analytical 
data of each compound is given below. 
 
N-Carbobenzoxy N´-butyltauramide (52b) 
 
Yield: 90 mg; 68%. 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 0.92 (3H, t, J 7.33, -CH3[11]), 
1.32-1.39 (2H, m, -CH2-[10]), 1.47-1.55 (2H, m, -CH2-[9]), 3.05-3.12 (2H, m, -CH2-[8]), 3.19 
(2H, t, J 6.05, -CH2-[6]), 3.63-3.69 (2H, m, -CH2-[5]), 4.48 (1H, br s, -NH-[7]), 5.1 (2H, s, -
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N-Carbobenzoxy N´-pentyltauramide (52c) 
 
Yield: 0.30 g, 75%. 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 0.89 (3H, t, J 6.84, -CH3[12]), 
1.25-1.32 (4H, m, -CH2-[10+11]), 1.55 (2H, s, -CH2-[9]), 3.0-3.1 (2H, m, -CH2-[8]), 3.1 (2H, 
t, J 5.98, -CH2-[6]), 3.63-3.69 (2H, m, -CH2-[5]), 4.5 (1H, br s, -NH-[7]), 5.1 (2H, s, -CH2-
[2]), 5.4 (1H, s, -NH-[4]) and 7.3 (5H, s, arom.[1]). 
 
N-Carbobenzoxy N´-hexyltauramide (52d) 
 
Yield: 0.32 g; 80%. 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 0.88 (3H, t, J 7.06, -CH3[13]), 
1.29-1.33 (6H, m, -CH2-[10+11+12]), 1.51-1.55 (2H, m, -CH2-[9]), 3.08-3.11 (2H, m, -CH2-
[8]), 3.2 (2H, t, J 6.13, -CH2-[5]), 3.63-3.69 (2H, m, -CH2-[6]), 4.52 (1H, br s, -NH-[7]), 5.1 
(1H, s, -CH2-[2]), 5.46 (1H, br s, -NH-[4])  and 7.33 - 7.35 (5H, m, arom.[1]). 
 
N-Carbobenzoxy N´-phenethyltauramide (52n) 
 
Yield: 0.11 g; 80 %. 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 2.85 (2H, d, J 6.8, -CH2-[9]), 3.06 
(2H, t, J 6.2, -CH2-[6]), 3.34-3.41 (2H, m, -CH2-[8]), 3.52-3.58 (2H, m, -CH2-[5]), 4.47 (1H, 
t, J 6.04, -NH-[7]), 5.09 (2H, s, -CH2-[2]), 5.4 (1H, br s, -NH-[4]) and 7.29 - 7.35 (10H, m, 
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N-Carbobenzoxy N´-methylcyclopropanetauramide (52h). 
 
 
Yield: 0.18 g; 69 %. 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 0.22 (2H, d, -H[10]), 0.54 (1H, s, -
CH-[9]), 2.92-3.00 (2H, m, -CH2-[8]), 3.22 (2H, t, J 6.07, -CH2-[6]), 3.64-3.70 (2H, m, -CH2-
[5]), 4.62 (1H, br s, -NH-[7]), 5.1 (2H, s, -CH2-[2]), 5.46 (1H, br s, -NH-[4]) and 7.32-7.35 
(5H, m, arom.[1]). 
 
N-Carbobenzoxy N´-benzyltauramide (52o) 
 
Yield: 0.26 g; 74%. 1H NMR (300 MHz; CDCl3; 25
o
C): δ 3.1 (2H, t, J 5.88, -CH2-[5]), 3.56 – 
3.64 (2H, m, -CH2-[6]), 3.72-3.78 (2H, m, -CH2-[8]), 4.9 (1H, s, -NH-[7]), 5.1 (2H, d, J 9.98, 
-CH2-[2]), 5.38 (1H, br s, -NH-[4]) and 7.30- 7.36 (10H, m, arom.[1 and 9]). 
 
N-Carbobenzoxy N´-ethylthioethyltauramide (52q) 
  
Yield: 0.15 g; 65%) 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 1.25 (3H, t, J 7.37, -CH3[11]), 
2.52-2.57 (2H, m, -CH2-[10]), 2.7 (2H, d, J 6.52, -CH2-[9]), 3.19-3.28 (4H, m, -CH2-[8+6]), 
3.64-3.70 (2H, m, -CH2-[5]), 4.98 (1H, br s, -NH-[7]), 5.1 (2H, s, -CH2-[2]), 5.45 (1H, br s, -
NH-[4]) and 7.33-7.36 (5H, m, arom. [1]). 
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4.3.3 Synthesis of N-substituted tauramides 
 
General method 
The N-carbobenzoxy N´-substituted tauramide 52 (0.20 g) was dissolved in methanol (4 mL) 
and the equivalent volume of concentrated HCl was added. The reaction mixture was stirred 
overnight under reflux, followed by addition of water (10 mL). The reaction mixture was 
washed with CH2Cl2, after which the aqueous phase was extracted and lyophilized to give the 





Yield: 0.10 g, 72%. 
1
H NMR (300 MHz; CDCl3; 25
o
C): δ 0.9 (3H, t, J 6.5, -CH3[9]), 1.33 
(4H, m, -CH2-[7+8]), 1.51 (2H, m, -CH2-[6]), 2.4 (2H, m, -CH2-[5]), 3.0 (2H, s, -CH2-[2]), 




Yield: 40 mg; 89%. 
1
H NMR (300 MHz; CDCl3; 25oC): δ 2.5 (2H, br s, -CH2-[6]), 2.9 (2H, 
br s, -CH2-[5]), 3.2-3.8 (4H, m, -CH2-[2 + 3]), 7.0 (1H, br s, -NH-[4]) and 7.9 (2H, br s, -
NH[1]). 
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4.3.4 Synthesis of N-substituted pantoyltauramides  
 
General method 
To a flask containing the N-substituted tauramide HCl salt 49 (0.10 g) was added 
pantolactone (2.5 eq.) and NEt3 (2.5 eq.). The reaction mixture was dissolved in ethanol (3 
mL) and refluxed with stirring for 7 hours. After cooling to room temperature, the solvent 
was evaporated and purified by flash chromatography (silica gel; 100% CH2Cl2) to 10% 
MeOH/ CH2Cl2) to afford the pure N-substituted pantoyltauramide 36. 
 
N-Pentyl pantoyltauramide (36c) 
 
 
Yield: 90 mg, 40%. 
1
H NMR (300 MHz; CDCl3; 25
o
C) δ 0.90 (3H, t, J 7.03, -CH3[13]),  0.96 
(3H, s, -CH3[14]),  1.04 (3H, s, -CH3[14]),  1.30-1.35 (4H, m, -CH2-[11+12]), 1.55-1.62 (2H, 
m, -CH2-[10]),  3.07-3.13 (2H, m, -CH2-[9]),  3.20-3.24 (2H, m, -CH2[1]), 3.53 (2H, s, -CH2-
[7]),  3.72-3.77 (2H, m, -CH2-[6]), 4.0 (1H, s, -CH-[3]), 4.9 (1H, t, -NH-[8]) and 7.43 (1H, br 
s, -NH-[5]).  
 
N-Phenethyl pantoyltauramide (36n)  
 
 
Yield: 0.10 g; 52%. 
1
H NMR (300 MHz; CDCl3; 25
o
C):  δ 0.93 (3H, s, -CH3[12]), 1.0 (3H, s, 
-CH3[12]), 2.88 (2H, d, J 6.62, -CH2-[10]), 3.0-3.1 (2H, m, -CH2-[9]), 3.38 (2H, t, J 6.84, -
CH2-[1]), 3.5 (2H, s, -CH2[6]), 3.6 (2H, t, J 5.47, -CH2[7]), 4.0 (1H, s, -CH-[3]), 4.96 (1H, br 
s, -NH-[8]) and 7.3 (1H, s, -NH-[5]). 
Stellenbosch University  http://scholar.sun.ac.za
79 
 
4.4 P. falciparum cell culture  
All in vitro experiments on malaria parasite was performed using P. falciparum strain 3D7 by 
Mr. Cristiano Macuamule. The parasites were synchronized in continuous culture and 
maintained in that state using a method described by Trager (81) and Cranmer et al (82) with 
further modification. In brief, the parasites were first cultured in group O, Rh
+
 erythrocytes 
suspended in RPMI-1640 culture medium to which was added 25 mM HEPES (pH 7.4), 11 
mM glucose, 200 µM hypoxanthine, 24 µg gentamycin/mL and 0.6% w/v Albumax II 
(complete media) giving a final hematocrit of ~5%. Cultures were grown horizontally in 
sealed tissue culture flasks gassed with a low O2 gas mix (1% O2, 3% CO2 in N2) with rotary 
shaking. The cultures were treated with 5% (w/v) Dsorbitol solution for a minimum of 10 
minutes at 37
o
C prior to using them for experiments so as to ensure that they are completely 
synchronized, as described (83). Fully matured trophozoite stage parasitized erythrocytes 
were subjected to lysis process leaving all parasites remaining in the ring stage. To reduce 
stress as a result of overgrowth, the medium was changed every day and cultures were split 
when parasites were mainly in trophozoite stage. Cultures were then split by using 1.25 mL 
of parasite infected erythrocytes isolated by centrifugation with the addition of 2 ml of fresh 
blood (100% hematocrit) in a final complete media volume of 50 ml giving a final hematocrit 
of ~5%. The level of parasitemia was determined by light microscopy counting a minimum 
of 500 erythrocytes on a Giemsa-stained thin blood smear and was kept between 5-15%. 
 
4.5 P. falciparum in vitro growth inhibition assays 
Determination of parasite proliferation was performed with the help of Mr. Cristiano 
Macuamule using a SYBR green assay as described by Smilkstein et al (84) and Bennett et al 
(85) with further modification. Procedures were performed in 96-well plates using ring-stage 
parasites with a hematocrit of 1% and 1% parasitemia were used. The malaria parasites were 
cultured in RPMI-1640 culture medium. The medium (contained 1 µM pantothenate), with a 
supplementation of 25 mM HEPES (pH 7.4), 11 mM glucose, 200 µM hypoxanthine, 24 µg 
gentamycin/mL and 0.6% w/v albumax II (complete media). Two-fold serial dilutions of 
pantothenamides and sulfonamides (ranging between 0.391-200 µM) were prepared in 
triplicate in a final volume of 200 µl. Normal red blood cells with a hematocrit of 1% was 
used as a blank; however, chloroquine (500 nM) was included as positive control. Infected 
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parasites cultured in the absence of pantothenamides and sulfonamides were includes to 
estimate 100% parasite growth. The prepared plates were incubated in a desiccator cabinet 
flushed with N2 gas mix (1% O2, 3% CO2, in N2) for 96 h at 37
o
C to allow the parasite to 
complete two life cycles. 
 
Parasite proliferation was determined by preparing fresh 96-well plates that contained 100 µL 
SYBR green solution in each well, comprising of 2 µL of SYBR safe DNA gel stain 
(10,000X concentrate in DMSO); in 10 mL lysis solution (20 mM Tris-HCl, 5 mM EDTA, 
0.008% w/v saponin, 0.08% v/v Triton X-100, pH 7.5). After 96 hour the plates containing 
the cultures were resuspended thoroughly and 100 µL of erythrocyte suspension was 
transferred to plate containing SYBR green solution, mixed properly until no visible 
erythrocyte sediment remained. The contents were then kept in the dark until plates were read 
by measuring the fluorescence, with excitation and emission wavelength bands at 490 nm and 
520 nm using a Varioskan multi-detection micro plate reader from ThermoLabsystems. The 
background fluorescence obtained were subtracted from each well by using the wells 
designated as blanks (containing uninfected erythrocytes) yielding fluorescence counts for 
analysis. 
 
4.6 Bacterial growth inhibition assays 
Inhibition studies were performed by preparing starter cultures of S. aureus RN4220 in 1% 
tryptone by inoculation with four separate colonies grown on LB agar plates. The starter 
culture was grown until OD600 of 0.62 and then diluted 10,000-fold in the same medium. A 
10% aliquot of the diluted cell suspension was used to inoculate each well of a 96-well flat-
bottomed plate containing 100 µL 1% tryptone broth supplemented with a specific N-
substituted pantothenamide in a final concentration of 200 µM. Final concentrations of 
compounds were between 0.039-200 µM. The plates were incubated at 37
o
C for 20 hours 
before the cell densities were measured by reading the absorbance in each well at 600 nm. 
The extent of growth in each well was determined by normalizing the OD600 values relative 
to those of negative control (containing 3% acetonitrile instead of pantothenamide), which 
were taken as 100% growth. Each compound was tested in triplicate and all experiments were 
repeated at least once after the initial experiment. 
  





5.1 Summary of results 
In this study 40 N-substituted α- and β-methylpantothenamides with different amide 
functionalities were successfully prepared by adapting an established method whereby such 
compounds can be prepared and synthesized in parallel.  These compounds tested as potential 
inhibitors of bacterial growth and the proliferation of malaria parasites. The synthesis of N-
substituted pantoyltauramides was also investigated, and three such analogues were 
successfully prepared and tested as inhibitors of P. falciparum parasites. 
 
The results of the biological studies show that the introduction of methyl functionalities does 
not improve the inhibitory properties of N-substituted pantothenamides in respect to bacteria. 
However, methylated pantothenamides show promise as improved inhibitors of P. falciparum 
growth. The same observation was also made for the N-substituted pantoyltauramides, which 
exhibited the best inhibition of all the inhibitors tested in this study. Taken together, these 
results indicate that the inhibitory properties of pantothenate analogues that act as 
antimetabolites can be improved by the introduction of new functional groups, or the 
modification of existing ones. 
5.2  Future research possibilities 
In future studies, the current set of pantothenamide analogues can be expanded by increasing 
the structural diversity on the β-alanine moiety to include other functionalities such as 
trifluoromethyl groups (CF3) or halogen functionalities (F and Cl). This could be achieved 
following the same strategy used in this study, where the functionality is introduced by using 
an appropriate β-alanine analogue to prepare the corresponding pantothenic acid analogue, 
the thioester, and eventually pantothenamide by parallel aminolysis and purification. 
 
Since the three pantoyltauramides have shown the potential of possessing inhibitory activities 
against malaria parasite proliferation, the structural diversity of the pantoyltauramides should 
also be expanded.  
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Future work should also include the biological testing of the newly prepared 
methylpantothenamides on bacteria other than S. aureus, such as E. coli and other bacteria 
that are known to accept pantothenamides as PanK substrates.  Studies will also need to be 
conducted to determine if these compounds have the same mode of action as the known 
pantothenamide inhibitors. It will also be important to evaluate the antibacterial properties of 
the three pantoyltauramides, since inhibitory studies were only done to investigate the 
antimalarial activities of these analogues on P. falciparum. Finally, the effect of pantothenate 
on the observed inhibition will have to be determined, to ensure that the improved inhibitory 
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Characterization of S-phenyl α- and β-methylthiopantothenate  





NMR, and by LC-MS analysis 
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Characterization of pantothenamides 
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Characterization of Cbz-tauramides 
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Characterization of pantoyltauramides 
All pantoyltauramides were characterized by 
1
H-NMR 
        
1







































































































Stellenbosch University  http://scholar.sun.ac.za
